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ABSTRACT OF THE DISSERTATION  
 
Kinetic Resolution of N-Acyl-β-Lactams, β-Lactams, and N-Acyl-Thiolactams Using 
Amidine-Based Catalysts 
by 
Valentina Bumbu 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis 2013 
Professor Vladimir Birman, Chair 
In the context of enantioselective nucleophilic acyl substitution, there are 3 types of processes 
depending where chirality is present: Type I, where the nucleophile (alcohol or amine) gets 
resolved, Type II, where chirality resides in the leaving group, and Type III, where a chiral acyl 
donor is attained in enantioenriched form. All these transformations can be used to physically 
separate enantiomers from a racemate in the presence of an asymmetric acylation catalyst and 
thus can be termed as “kinetic resolutions” or KR. Considerable progress has been done in the 
Type I transformation, where chiral alcohols, thiols, and amines are achieved with great 
selectivities via asymmetric enzymatic and non-enzymatic acylation. KR of chiral acyl donors 
(Type III) has also been accomplished using both enzymatic and non-enzymatic modes of 
catalysis. However, Type II process has only been reported enzymatically. 
Since 2003 our group has developed 4 consecutive generations of amidine-based catalysts 
(ABCs) that have engaged in a variety of enantioselective acylation transformations, mostly 
xvii 
 
Type I (KR of various alcohols and lactams (and thiolactams) via asymmetric acylation) and 
Type III (enantioselective alcoholysis of α-substituted acids and azlactones) processes.  
As a contribution and an extension to enantioselective, catalytic, nucleophilic acyl substitution 
study with ABCs, my work has left a mark in all three types of processes discussed above. An 
unprecedented KR of N-acyl-β-lactams via enantioselective alcoholysis (Type III) has been 
achieved with great results. The established protocol leads to preparation of β-amino acids 
derivatives in enantioenriched form. Equally unique in this transformation is the mode of action 
of ABCs, where for the first time the nucleophilic attack of our catalysts on chiral acyl donors 
was in itself highly enantioselective – a phenomenon in contrast to usual behavior of ABCs in 
previously studied processes in our lab. Similarly novel, or at least conceptually, was the 
accomplishment of the first asymmetric de-acylation (Type II) process reported to date using 
non-enzymatic acyl transfer catalyst in the form of asymmetric alcoholysis of N-acyl-
thiolactams. The KR poses an alternate route to obtaining enantioenriched thiazolidin-2-thiones 
and oxazolidine-2-thiones. And last but not least, the first enantioselective N-acylation of β-
lactams (a Type I process) has been obtained with acceptable to good selectivities. This method 
complements the enantioselective alcoholysis of N-acyl-β-lactams, since it achieves unscathed 
enantioenriched β-lactams.  
 
1 
 
Chapter I 
Introduction to Nucleophilic Acyl Substitution. Fundamentals and 
Terminology. 
 
1.1 Types of enantioselective nucleophilic acyl substitution in kinetic resolution 
Enantioselective acyl substitution reactions may be classified according to the location of 
the stereogenic centers: 1) in the nucleophile Y (Type I); 2) in the leaving group X (Type II); or 
3) in the acyl group (Type III) (Figure 1.1-1).  
Figure 1.1-1: Three ways to induce chirality in asymmetric nucleophilic acyl substitution 
 
 
 
These three types of processes can be exemplified by using formation and hydrolysis of 
esters as shown in Figures 1.1-2 and 1.1-3. In Type I process (Figures 1.1-2, left) an achiral 
acyl donor acylates one of the enantiomers of a racemic alcohol forming an ester, while the other 
enantiomer remains mostly unreacted. In Type II transformation, the reverse happens (Figures 
1.1-2, right): one of the enantiomers of a racemic ester is hydrolyzed selectively. Type I and II 
processes will produce the same mixture of the enantioenriched alcohol and ester, if their 
enantioselectivities are opposite. Both enantioselective esterification of a chiral acid and the 
complementary hydrolysis of the corresponding ester belong to Type III process. 
i Of course, additional possibilities may arise from various combinations of individual types of processes. For 
example, enantioselective hydrolysis of a racemic lactone may be viewed as a “mixed” Type II-Type III process 
2 
 
Figure 1.1-2: Examples of Type I and II processes  
 
 
 
                                                                                                           
 
 
 
 
Figure 1.1-3: Examples of Type III process 
 
All of the aforementioned transformations can be used to achieve physical separation of a 
racemic mixture into individual enantiomers and, thus, can be termed “kinetic resolutions” or 
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KR1.   By IUPAC definition, “KR is the achievement of partial or complete resolution by virtue 
of unequal rates of a reaction of the enantiomers in a racemate with a chiral agent (reagent, 
catalyst, solvent, etc.)”. All three types of enantioselective nucleophilic acyl substitutions 
discussed above have been successfully carried out using enzymes2. Considerable progress has 
also been made in the development of non-enzymatic asymmetric acylation catalysts. They have 
accomplished considerable success especially in the KR of alcohols and, to a lesser extent, 
amines and thiols (Type I).3 However, until recently, there have been no reports of these 
catalysts working in the “reverse” to achieve enantioselective deacylation (Type II). The first 
non-enzymatic example of such a transformation can be found in Chapter IV of this thesis.  
Several examples of Type III process (enantioselective alcoholysis of activated chiral acyl 
donors) have also been achieved using non-enzymatic catalysts.4 
The efficiency of KR is often described by selectivity factor (s), which is the ratio of 
relative rate constants of the two enantiomers (s = kfast/kslow) (Scheme 1.1-1).5 S-value remains 
unchanged throughout the progress of a reaction unlike enantiomeric excess (ee), which changes 
in the course of KR.  
Many common asymmetric catalysts that have been effective in catalyzing acylation 
reactions are just chiral versions of simpler achiral catalysts, such as 4-dialkylaminopyridines 
(i.e. DMAP)6, N-alkylimidazoles (i.e NMI)7, phosphines (i.e. tributylphosphine)8,  N-
heterocyclic  carbenes (NHC)9  (Figure 1.1-4).  They are believed to operate through a similar 
catalytic cycle via an acyl transfer mechanism.   In the step I, the nucleophilic catalyst :Nu in the 
presence of an acyl donor  RCOX would form a reactive intermediate (usually a zwitterionic 
4 
 
salt), which gets attacked by a sufficiently nucleophilic substrate Y-H in step II, forming product 
RCOY and releasing the catalyst :Nu for subsequent reuse.  
Scheme 1.1-1: Determination of selectivity factor (s) in KR 
 
  
       eeP                                 eeSM 
 
 
 
                                           [S]-[R] 
 
Calculated for s = 7 
 
Figure 1.1-4: Common achiral acylation catalysts and catalytic cycle 
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1.2 Acyl trasfer catalysts designed in our group and their application in Types I-III 
processes 
From 2003 till 2009, our group designed and synthesized four consecutive generations of 
amidine-based catalysts (ABCs) I-1 through I-4 that operate via an enantioselective acyl transfer 
mechanism10 (Figure 1.2-1). Their advantages are simple design, ease of preparation, versatility, 
and high enantioselectivity. 
Figure 1.2-1: Amidine-Based Catalysts developed in our group 
 
 
 
 
 
Prior to the studies described in this thesis, ABCs demonstrated their efficacy in Type I 
KR of various secondary alcohols (benzylic, allylic, propargylic, cyclic)11, displaying good to 
excellent selectivity factors (Scheme 1.2-1, s-value in bold color corresponding to the catalyst 
used in the study, % conversion in [brackets]).  Based on experimental results later confirmed by 
computational studies of transition state (TS) models in KR of benzylic alcohols, the catalysts’ 
mode of action has been described by π-cation interactions between the nucleophilic substrate 
and the N-acylated catalyst12. Later, ABCs were used to resolve oxazolidinones, with a similar 
mechanism to the one of alcohols (Scheme 1.2-2).13  
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32 [52%]
n-Bu
Me
OH
OMe
31 [56%]
Me
OH OH
112 [52%]
Scheme 1.2-1: KR of 2º alcohols using ABCs and TS model with CF3-PIP   
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2-2: KR of oxazolidiones using ABCs 
 
ABCs have also proved to be successful in less explored Type III transformation with 
KR of acyl donors – a study pioneered by Xing Yang in our group. One could envision 
mechanistic similarities between the KR of alcohols and acyl donors, yet in the latter both acyl 
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activation and alcoholysis steps in the catalytic cycle could result in enantiodiscrimination 
(Scheme 1.2-3). 
Scheme 1.2-3: KR of alcohols (Type I process) vs KR of acyl donors (Type III process) 
 
 
 
 
 
 
 
Xing demonstrated that HBTM can resolve various α-substituted carboxylic acids with 
good enantioselectivities14 (Scheme 1.2-4, A). Furthermore, Xing was able to accomplish the 
dynamic kinetic resolution (DKR) of α-arylthio- and α-alkylthio-alkanoic acids with great ees 
and yields15 (Scheme 1.2-4, B). Unlike conventional KR, DKR is based on a rapid in situ 
equilibration between fast- and slow-reacting enantiomers. Hence, it is a more efficient process 
since it can generate up 100% yield of only one enantioenriched product. In both cases (KR and 
DKR), Xing noticed that enantioselectivity was strongly dependent on the nature of alcohol used.  
The need to use the bulky di(1-naphthyl)methanol indicated that the second step in the catalytic 
cycle determined enantiodifferentiation, analogously to previously studied acylation of alcohols 
and oxazolidinones (Figure 1.2-2). Experimental results, later confirmed by computational 
studies16, suggested the origin of enantioselectivity stemmed from cation-π interaction between 
the bulky alcohol and acylated HBTM and that the alcohol attack was according to the polar 
Felkin-Ahn model17. Another example of Type III process accomplished by Xing in 
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collaboration with Guojian Lu was the DKR of azlactones.18 This work served as a point of 
reference for the subsequent studies discussed in Chapter II and, hence, will be described in more 
detail later.  
Scheme 1.2-4: KR (and DKR) of α-substituted carboxylic acids using HBTM  
 
 
 
 
 
 
 
 
Figure 1.2-2: Proposed catalytic cycle and TS model in the KR (or DKR) of α-substituted acids 
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In the following chapters of this thesis, I will be describing my contribution in the 
enantioselective nucleophilic acyl substitution field, apart from what has been discussed above. I 
was fortunate to have had my work leave a mark in all Types I-III processes using ABCs 
developed in our group. 
1.3 References 
1 For a review of resolution methods, see: a) Faigl, F; Fogassy, E.; Nógrádi, M.; Pálovics, E.; 
Schindler, J. Tetrahedron Asymm., 2008, 19, 519.  
2 Drauz, K.; Gröger, H.; May, O; Eds. In Enzyme Catalysis in Organic Synthesis, 3rd Ed., Vol. 1; 
Wiley-VCH: Weinheim, Germany 2012. a) For enantioselective acylation of alcohols, see pp. 
302-334. b) For asymmetric enzymatic de-acylation of esters to form chiral alcohols, see pp 284-
291. c) For enantioselective esterefication of chiral acids, see pp 334-337. 
3 For recent reviews, see: a) Krasnov, V. P.; Gruzdev, D.A.; Levit, G. L. Eur. J. Org. Chem. 
2012, 1471. b) Müller, C. E.; Schreiner, P. R., Angew. Chem., Int. Ed. 2011, 50, 6012. c) 
Pellissier, H. Adv. Synth. Catal. 2011, 353, 1613. d) Spivey, A. C.; Arseniyadis, S. Top. Curr. 
Chem. 2010, 291, 233 
4 For some examples of non-enzymatic KR of acyl donors, see: a) Narasaka, K.; Kanai, F.; 
Okudo, M.; Miyoshi, N. Chem. Lett. 1989, 1187. b) Tian, S.-K.; Chen, Y.; Hang. J.; Tang. L; 
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Chapter II 
Kinetic Resolution of N-Acyl-β-Lactams via Enantioselective Alcoholysis 
using Amidine-based Catalysts 
 
2.1   Introduction  
Due to their specific biological properties, β-amino acids and their derivatives have been 
known and used in various applications1. There are many approaches to their preparation in 
enantiopure form, one of which is through ring opening of enantioenriched β-lactams or β-lactam 
derivatives2. Despite the breakthroughs in the asymmetric synthesis of the latter, the β-lactam 
substrate scope often remained limited3. Hence, the enzymatic hydrolysis of their racemates4 still 
remains a viable method for preparing enantiopure β-amino acids5 (Scheme 2.1-1). Despite their 
high efficacy, enzymes have serious shortcomings, such as availability only in one enantiomeric 
form, narrow substrate or reaction scope, and/or, at times, high cost.  
Scheme 2.1-1: Enzymatic approaches to KR of β-lactams 
 
 
 
 
 
Although non-enzymatic kinetic resolution (KR) of β-lactam racemates would be an 
attractive method to obtain enantioenriched β-amino acids, to the best of our knowledge, it has 
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not been reported until our work in this area6,7. Hence, in this chapter, I will be describing the 
first enantioselective alcoholysis of β-lactam derivatives and my efforts to elucidate the 
mechanism of this process using ABCs I-2 through I-4.   
In the investigation of KR of various chiral acyl donors8, Xing Yang in collaboration with 
Guojian Lu has developed a protocol for DKR of azlactones9 (Scheme 2.1-2) to obtain 
enantioenriched α-amino acids. They have noticed that changing   the amount of benzoic acid   
relative   to the catalyst did not have a significant effect on the reaction rate or enantioselectivity, 
although in its absence the reaction did not seem to proceed at all. Such activation with Brønsted 
acid in combination with an enantioselective acyl transfer catalyst has been previously reported 
by others.10 Apart from that, the catalytic cycle and catalyst’s mode of action in this process 
seemed to be consistent with ABCs previous behavior (Figure 2.1-1)8, 11, 12. The success of the 
DKR of azlactones with BTM led me to investigate other classes of chiral acyl donors that could 
use a combination of ABC with a Brønsted acid and that would generate enantioenriched 
products of practical use. 
Scheme 2.1-2: DKR of azlactones 
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Figure 2.1-2: Proposed catalytic cycle and origin of enantioselectivity in DKR of azlactones 
 
 
  
 
 
 
 
    
2.2    Experimental design and findings 
Initially we turned our attention to oxazinones, the ring-expanded homologues of azlactones, 
which would lead to enantioenriched β-amino acid derivatives. The KR of oxazinones has been 
previously achieved by Berkessel et al using a bifunctional thiourea catalyst with impressive 
selectivities13. When 4-phenyl oxazinone II-1 was subjected to KR with di(1-naphthyl)methanol 
in the presence of our catalytic system it did react, however, the selectivity was disappointingly 
low  (Table 2.2-1, entry 1). Interestingly, when less hindered alcohols were used, the results 
were approximately the same (entries 2,3).  
Table 2.2-1: KR of oxazinone (±)-II-1: Alcohol screeninga 
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Entry R Conversion (%) s 
1 (1-Np)2CH (II-2a) 56 3.9 
2 PhCH2 (II-2b) 51 2.9 
3 Me (II-2c) 48 3.3 
Reaction conditions:  0.1 mmol (±)-II-1, 0.05 mmol  ROH, (S)-BTM (10 mmol%), PhCO2H (10 mmol%), in CDCl3, 
rt. [a] Results averaged from duplicate runs 
 
This suggested that the mechanism of this transformation might be entirely different from 
what was observed in the DKR of azlactones, where enantioselectivity depended critically on the 
alcohol used. The absence of such dependence in the case of oxazinones indicated to us that 
enantioselectivity might arise in the first step in the catalytic cycle. Witnessing a new 
phenomenon, we were excited about its prospects despite initial disappointing results. Therefore, 
we decided to try the KR of N-acyl-β-lactam II-3a, the constitutional isomer of II-1   (Figure 
2.2-1). Since II-3a would produce the same reactive intermediate II-4 upon ring-opening as II-1, 
we reasoned that the N-acyl-β-lactam could potentially undergo KR in similar fashion to II-1 in 
the presence of BTM, but hopefully with better enantioselectivity. 
Figure 2.2-1: Proposed catalytic cycle for oxazinone II-1 and N-acyl-β-lactam II-3a  
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Gratifyingly, when I tried the KR conditions with di(1-naphthyl)methanol on N-bezoyl-4-
phenyl-β-lactam II-3a, the selectivity significantly improved (Table 2.2-2, entry 1). 
Furthermore, again, switching to less hindered alcohols gave essentially the same results with 
this substrate (entries 2,3), suggesting a similar mechanism as in the case of oxazinone II-1 
(Figure 2.2-1). This observation seemed to indicate that the enantioselectivity–determining step 
is irreversible and that N-acyl-β-lactams are more suitable substrates for appreciable induction of 
asymmetry during the nucleophilic attack of our catalyst than oxazinones.     
Table 2.2-2: KR of N-acyl-β-lactam (±)-II-3a: Alcohol screeninga 
 
 
 
 Entrya R Time (hrs) Conversion (%) s 
1 (1-Np)2CH (II-2a’’’) 68 51 21 
2 PhCH2 (II-2a’’) 68 52 19 
3 Me (II-2a’) 24 52 21 
General conditions: 0.1 mmol (±)-II-3a, 0.5 mmol ROH, 10 mol% (S)-BTM, 10 mol% PhCO2H, in CDCl3, rt.         
[a] Results averaged from duplicate runs 
 
As part of the optimization study, I briefly investigated whether a Lewis acid (LA) could 
also be applied to the catalytic alcoholysis of N-acyl-β-lactam II-3a with comparable mode of 
action to benzoic acid. It was a challenge, however, to find common Lewis acids that would 
dissolve in chloroform and, hence, to run accurate and reproducible experiments (I could not 
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make stock solutions and working with very small amounts of Lewis acids could have led to 
experimental errors). When LiBF4 was tried in the KR of II-3a with benzyl alcohol, despite its 
poor solubility, it did give similar selectivity and reaction times to the case of benzoic acid 
(Scheme 2.2-1). 
Scheme 2.2-1: KR of N-acyl-β-lactam (±)-II-3a in presence of a Lewis Acid  
 
 
 
 
 
Mindful of the fact that LAs could potentially catalyze alcoholysis of the substrates by 
themselves, a qualitative background test with several Lewis acids varying in potency was 
performed (Table 2.2-3). These results indicate that some LAs, Sc(OTf)3 and Cu(OTf)2, do 
indeed catalyze the alcoholysis of N-acyl-β-lactams. This observation could provide some ideas 
for future new designs of asymmetric catalysts including the corresponding metals. Since LAs 
did not offer any apparent advantages compared to benzoic acid, we continued to use the latter in 
our optimization study. 
Table 2.2-3: Lewis acid background reaction check for N-acyl-β-lactam (±)-II-3a 
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Entry Lewis Acid (10 mol%) Solubility of LA 
in CDCl3  
Time Background reaction 
1 LiCl Not soluble 40 hrs no 
2 Mg(ClO4)2 Not soluble 40 hrs no 
4 Sc(OTf)3 Not soluble 17 hrs Only ester product observed 
6 Cu(OTf)2 Not soluble 17 hrs Only ester product observed 
7 Zn(OTf)2 Not soluble 40 hrs no 
8 ZnBr2 Not soluble 40 hrs no 
Reaction conditions: 0.1 mmol (±)-II-3a and 0.1 mmol BnOH in CDCl3, 0.01 mmol Lewis Acid, rt. 
We then proceeded to test our other most potent ABCs, HBTM I-4a and Cl-PIQ I-2 
(Table 2.2-4). Although the alcoholysis occurred in both cases, the KR proved to be less 
enantioselective than in the one of BTM ent-I-3 (Entries 3,4 vs 2). As expected, no reaction 
happened in the absence of catalyst (entry 1). 
 Table 2.2-4: KR of N-acyl-β-lactam (±)-II-3a: Catalyst screeninga 
 
 
Entrya Catalyst Time (days) Conversion (%) s 
1 none 1 NRb NDc 
2 (S)-BTM ent-I-3 1 60 18 
3 (S)-HBTM I-4a 3 62 12-1 
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4 (R)-Cl-PIQ I-2 7 42 2.5-1 
General conditions: 0.1 mmol (±)-II-3a, 0.075 mmol ROH, catalyst (10 mol%), PhCO2H (10 mol%), in CDCl3, rt. 
[a] Results averaged from duplicate runs. [b] Determined by H1 NMR. [c] No reaction. [d] Not determined 
 
The variation of acyl group on the β-lactam nitrogen was explored next (Table 2.2-5). 
Both N-Boc II-3b and N-isobutyryl II-3c derivatives were unreactive (entries 2,3). Introducing 
an electron-withdrawing group to the benzoyl substituent proved to affect both the rate and the 
enantioselectivity in this process. 4-Chlorobenzoyl derivative underwent KR with an appreciable 
enhancement of selectivity factor with similar rate compared to the benzoyl compound (entry 4). 
When reaction was run at 0 °C, the enantioselectivity did improve notably, but the rate was much 
too slow to be considered practical (entry 5). However, 4-Nitrobenzoyl group demonstrated, as 
expected, the acceleration in methanolysis rate led to a diminished enantioselectivity (entry 6). 
The selectivity factor did not improve when the temperature of the reaction was lowered to 0 ºC 
(entry 7). 3,5-Dinotrobenzoyl substrate II-3f underwent ring-opening even faster, but with 
considerably lower selectivity factor (entry 8). 
Table 2.2-5: KR of N-acyl-β-lactam (±)-II-3a: N-acyl group screeninga   
 
   
Entrya R Time Conversion (%) s 
1 Ph 24 hrs 60 18 
2 OBu-t (II-3b) 7 days NR ND 
3 Me2CH (II-3c) 7 days NR ND 
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4 p-ClC6H4 (II-3d) 20 hrs 53 26 
5b p-ClC6H4 (II-3d) 7 days 51 37 
6 p-NO2C6H4 (II-3e) 5 hrs 53 20 
7b p-NO2C6H4 (II-3e) 36 hrs 50 20 
8 3,5-(NO2)2C6H4 (II-3f) 1 hrs 72 2.6 
General conditions: 0.1 mmol (±)-II-3, 0.05 mmol MeOH, 10 mol% (S)-BTM, 10 mol% PhCO2H, in CDCl3, rt.    
[a] Results based on duplicate runs [b] Reaction conducted at 0 ºC. 
 
Due to the limited solubility of N-benzoyl-β-lactams, the solvent screening was a 
relatively short process (Table 2.2-6). The substrate II-3d dissolved best in chloroform and 
methylene chloride, the latter leading to a lower selectivity factor (entry 2 vs 1). Toluene gave 
comparable enantioselectivity to chloroform, albeit at a more sluggish rate (entry 3). 
Additionally, it was a poor medium for a smooth KR as the starting material precipitated out 
within minutes from the beginning of reaction despite a decrease in concentration, affecting the 
accuracy of results. Although the substrate displayed better solubility in acetonitrile than toluene, 
the selectivity suffered significantly (entry 4). Tetrahydrofuran seemed to be an unsuitable 
solvent for this system altogether, as the reaction was very slow and led to undesired side 
products that complicated the purification and analysis process (entry 5).  
Table 2.2-6: KR of N-acyl-β-lactam (±)-II-3d: Solvent screeninga 
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Entrya Solvent Time (days) Conversion (%) s 
1 CDCl3 1.5 47 28 
2 CD2Cl2 3.5 55 20.5 
3 d8-toluene 7 38 29 
4 CD3CN 3.5 54 12 
5 d8-THF 7  20b ND 
General conditions: 0.1 mmol (±)-II-3d, 0.075 mmol MeOH, 10 mol% (R)-BTM, 10 mol% PhCO2H, in solvent, rt. 
[a] Results based on duplicate runs [b] Determined by H1 NMR 
  
Once the optimization process was completed, we began to investigate the substrate 
scope (Table 2.2-7). Surprisingly, having R3 changed from phenyl to 1-napthyl improved 
enantioselectivity only slightly (entry 2 vs 1), while isopropyl substituent gave an unexpectedly 
impressive selectivity factor of 78 (entry 3). To our delight, once cis-ring-fused N-acyl-β-lactams 
from II-7 to II-12  were subjected to the same KR conditions, the results were even more 
exciting, enantioselectivities ranging from 111 to 211 (entries 4-9). Unfortunately, when we 
switched to trans-disubstituted monocyclic substrate II-13, it failed to react completely over the 
course of one week (entry 10).   
Table 2.2-7: KR of N-acyl-β-lactams: Substrate scopea 
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Entry Substratea,b    Time eePR 
(%) 
eeSM 
(%) 
Conv (%) s 
1 
II-3d 
20 h 79 90 53 26 
2 
II-5  
22 h 78 95 55 30 
3 
II-6  
3 d 93 84 47 78 
4 
II-7  
56 h 96 92 49 166 
5 
II-8  
24 h 89 99.8 53 111 
6 
II-9  
4 d 97 81 45 196 
7 
II-10  
7 d 98 59 38 211 
8 
II-11  
66 h 95 95 50 156 
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TM I 3
MeOH
CO2H
Cl3, rt
CO2Me
NHR1
+
NR1
OH
H
95.2% ee 93.0% ee
time = 72 hrs conv = 49% s = 140
45% yield 47% yield
catalyst recovery: 76%
9 
II-12  
32 h 96 82 46 124 
10 
II-13  
7 d ND ND NR ND 
General conditions: 0.1 mmol (±)-substrate, 0.075 mmol MeOH, 10 mol% (S)-BTM, 10 mol%  PhCO2H, in CDCl3, 
rt. [a] Results based on duplicate runs. [b]The absolute configuration of the fast reacting enantiomer shown. 
 
 
To demonstrate the practical utility of this process, the KR of substrate II-11 on a 1-gram 
scale was performed, giving similar results to the small scale KR of the same substrate, with 
excellent yields of enantioenriched species and a 76% catalyst recovery (Scheme 2.2-2).        
 Scheme 2.2-2: Preparative-scale KR of N-acyl-β-lactam (±)-II-11 
    
 
 
 
 
 
To explain the origin of enantioselectivity, we initially envisioned that the catalyst would 
prefer a facial attack on β-lactam carbonyl with the N-benzoyl group away from the catalyst’s 
phenyl substituent at C-2 to avoid steric interactions with the ring hydrogens (Figure 2.2-2).  
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Figure 2.2-2: Initial proposed model for enantiodiscrimination in KR of N-acyl-β-lactams  
 
The proposed model also explained the increase in enantioselectivity with cis-ring-fused 
substrates and lack of reaction with trans-substituted N-acyl-β-lactams. Having R2 and R3 groups 
cis to each other would only enhance the blockage on the face they are pointing towards, while 
trans substitution would hinder the catalyst attack from either face. The model excluded the acid, 
since it was unclear to us at that time what role it played.  
Subsequent preliminary computational studies on II-3a, however, demonstrated that our 
initially proposed model was too simplistic, even if it accounted for the available experimental 
results (Figure 2.2-3). The transition states were built with Xing Yang’s help introducing two 
important interactions, not taken in consideration in our initial proposed model for 
enantiodifferentiation: 1) the π-cation interaction between the benzothiazolium moiety and 
phenyl in the aroyl group of N-acyl-β-lactam and 2) the S-O interaction, where the amide 
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carbonyl from the β-lactam core lies in the same plane as the catalyst and is directed toward its 
benzothiazolium part (Figure 2.2-3). Throughout this study, the method used was Gaussian, 
DFT B3LYP/3-21G(d). According to these preliminary calculations, the fast-reacting enantiomer 
(in TS-(S)-BTM-(R)-II-3a) was favored energetically by 4.5 kcal/mol over the slow-reacting 
enantiomer (TS-(S)-BTM-(S)-II-3a), presumably due to taking advantage of the π-cation 
stacking. The S-O interaction stays prevalent in both TSs (~2.5 Å). That said, please note that 
these studies are crude and might provide only qualitative clues to the substrate chiral 
recognition in this KR. Additional research needs to be performed to explore all possible TSs 
before we can confirm that the proposed draft models do indeed represent the global minima. 
Those have not yet been carried out due to limited time and demand of expertise in 
computational chemistry and software. 
Figure 2.2-3: Preliminary computational studies of TSs of fast- and slow-reacting enantiomers 
of II-3a  
 
 
 
 
 
 
 
 
                   TS-(S)-BTM-(R)-II-3a                                               TS-(S)-BTM-(S)-II-3a                       
                  ∆∆G‡= 0.0 kcal/mol                                                 ∆∆G‡= 4.5 kcal/mol 
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2.3    An extension to the study on other modes of catalysis and the role of the Brønsted acid 
in the KR of N-acyl-β-lactams 
After examining enantioselective alcoholysis of N-acyl-β-lactams promoted by ABCs14, 
we were curious whether other known types of asymmetric catalysts might also be effective in 
this process. Keeping in mind that chiral thioureas were highly successful in the alcoholysis of 
azlactones15 and oxazinones13a, we tested the catalysts II-14 through II-16 available in our lab. 
Among these only II-15 proved to be catalytically active in the KR of II-11. However, the 
enantioselectivity was low (Table 3.2-1, entry 2). Switching the solvent to toluene or acetonitrile 
did not change the outcome (entries 3, 4). Chiral phosphoric acid-based catalyst II-17 previously 
identified in our lab by Guojian Lu as an efficient catalyst in the DKR of azlactones16, also 
turned out to be completely ineffective (entry 5).   
Table 2.3-1: KR of N-acyl-β-lactam (±)-II-11: Screening of other catalystsa 
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General conditions: 0.05 mmol (±)-II-11, 0.025 mmol MeOH, 10 mol% catalyst, in CDCl3, rt, unless otherwise 
specified. [a] Results averaged from duplicate runs. [b] Reaction conducted in toluene. [c] Reaction conducted in 
acetonitrile 
 
We soon shifted our attention to the investigation of the role of acid (benzoic acid in this 
case) in the KR of N-acyl-β-lactam. Initially we thought that Brønsted acid (or Lewis acid) was 
paramount to the KR of N-acyl-β-lactams, as in the case of the DKR of azlactones, where the 
reaction would not proceed at all in its absence. However, when benzoic acid was omitted from 
our standard alcoholysis protocol, the ring-opening did occur, albeit with a reduced selectivity 
(Scheme 2.3-1). We also noticed the formation of a side product by H1 NMR that was not 
observed previously in the presence of PhCO2H. The initial attempt to collect it and analyze it 
after purification failed, as it would decompose on silica gel. We came to suspect, however, that 
the mysterious side product might be the isomeric oxazinone II-1a. That indeed was the case 
when compound II-1a was synthesized according to a modified procedure established by 
Berkessel et al13. The unique sets of doublet of doublets at 5.04, 3.04, and 2.64 ppm of II-1a 
matched very closely the ones of previously reported II-1 (5.07, 3.06, and 2.68 ppm).  
 
Entrya Catalyst Time 
(days) 
eePR (%) eeSM (%) Conv (%) s 
1 II-14 4  ND ND NR ND 
2 II-15 4  51 25 34 4 
3b II-15 4  44 39 47 4 
4c II-15 4  13 6 30 1.4 
5 II-16 4  ND ND <10 ND 
6 II-17 7  ND ND NR ND 
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Scheme 2.3-1: KR of N-acyl-β-lactam (±)-II-3d in the absence of benzoic acid  
 
 
 
 
We initially reasoned that the formation of an oxazinone, which KR was not as effective 
as in the case of N-acyl-β-lactams under our protocol, might be the culprit of lower ester 
enantioselectivity when acid was not added. For that to be true we needed to demonstrate that the 
oxazinone II-1a formed was not enantioenriched.  To measure the ee and monitor the formation 
of oxazinone over time, KR of N-acyl-β-lactam II-3d was run in the presence and absence of 
benzoic acid and analyzed by H1 NMR using 2,6-methoxytoluene as an internal standard 
(Scheme 2.3-2). In the absence of acid, we noticed that initially ester and oxazinone were 
forming at approximately the same rate, but at around the 4th hour the ester stopped forming 
while the N-acyl-β-lactam continued to get consumed, leading to more oxazinone in solution. 
Furthermore, after careful purification and analysis, the oxazinone II-1a’s ee was comparable to 
that of unreacted starting material and ester. This process was a case where we formed 3 
enantioenriched species and we no longer could discuss enantioselectivity in terms of conversion 
and selectivity factor as we did in Chapter I, 1.1. We used an alternative equation, also devised 
by Kagan16, to calculate the selectivity factor to account only for the product formed: s = ln[1-
C(1+eePR)]/ln[1-C(1-eePR)], where C (% conv) was determined by 1H NMR. On the other hand, 
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in the presence of acid, oxazinone II-1a was barely detectable by H1 NMR, which explained why 
it has not been noticed before.  
Scheme 2.3-2: KR of N-acyl-β-lactam (±)-II-3d in the presence and absence of acid  
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All these findings were puzzling to us, because although we had more details on the 
acid’s mechanistic role, we could not explain why the ees were lower in the absence of acid. The 
opening of the oxazinone under this catalytic system would produce product ester equally or very 
similarly enantioenriched as the one produced by opening the fast-reacting N-acyl-β-lactam 
enantiomer. That said, it is noteworthy to mention a 10% discrepancy between the percentage of 
N-acyl-β-lactam used and the percentage sum of products formed, which may be due to 
inaccuracy in weighing of reagents and/or analyzing 1H NMR spectra.  
To get more insights on the mechanism of this transformation, a series of reactions were 
performed by tweaking the catalytic system (Table 2.3-2). As expected, no reaction happened in 
the absence of catalyst within 24 hours, with or without benzoic acid (entries 5, 4). We were 
wondering if increasing the amount of acid in the presence of our catalyst would further improve 
the selectivity factor, and that did not seem to be the case when amount of benzoic acid was 
changed to 20 mol% or 50 mol% (entries 2, 3). Eliminating the possibility that this process might 
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be base catalyzed, BTM I-3 was substituted with 1 equivalent of 2,6-collidine and only 15% 
conversion after 48 hours was observed (however, no ester peaks were visible after 24 hours).     
Table 2.3-2: KR of N-acyl-β-lactam (±)-II-3d: Testing the catalytic system 
 
 
 
 
 
Entry Additives Time eeester eeβ-lac eeox Conv (%) s 
1a, b 10 mol% (R)-BTM +      
20 mol% PhCO2H 
24 hrs 82.8 82.9 ND 50 27 
3b,c 10 mol% (R)-BTM +      
50 mol% PhCO2H 
24 hrs 81.0 89.6 ND 52.5 29 
4 none 24 hrs ND ND ND NRd NA 
5e 10 mol% PhCO2H 24 hrs ND ND ND NRd NA 
6f 1 equiv 2,4,6-collidine 48 hrs ND ND ND 15d NA 
Reaction conditions: 0.1 mmol (±)-II-3d, 0.075 mmol MeOH, 0.75 mL CDCl3, rt, unless otherwise specified. [a] 0.1 
mmol (±)-II-3d, 0.075 mmol MeOH, 10 mol% (R)-BTM, 0.1 mmol 2,6-methoxytoluene, 20 mol%  PhCO2H, 
inCDCl3, rt. [b] Results based on a single run. [c] 0.1 mmol (±)-II-3d, 0.075 mmol MeOH, 10 mol% (R)-BTM, 0.1 
mmol 2,6-methoxytoluene, 50 mol%  PhCO2H, inCDCl3. [d] Determined by H1 NMR. [e] 0.1 mmol (±)-II-3d, 0.075 
mmol MeOH, 0.1 mmol PhCO2H, 0.75 mL CDCl3, rt. [f] 0.1 mmol (±)-II-3d, 0.075 mmol MeOH, 0.1 mmol 2,4,6-
collidine, in CDCl3, rt. 
 
With no methanol in the reaction medium, we could technically achieve the KR of N-
acyl-β-lactams to obtain enantioenriched oxazinones (Scheme 2.3-3). This in itself could be an 
interesting study to be investigated alone. Again the presence of Brønsted acid made a difference 
in the selectivity factor and reaction times. Albeit the reaction occurred at a slower rate, the acid 
seemed to contribute somehow towards higher enantioselectivity (s = 45 vs 35).  
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Scheme 2.3-3: KR of N-acyl-β-lactam (±)-II-3d in the absence of methanol 
 
 
 
 
 
 
 
Interestingly, when the KR of oxazinone II-1a was investigated in the presence and 
absence of acid, it was not a discrepancy in selectivities that became visible, but in rates 
(Scheme 2.3-4). Using benzoic acid, the KR happened three times faster compared to KR in the 
absence of acid. This could suggest that the acid not only hindered the formation of oxazinone 
but also sped up its alcoholysis (in case any oxazinone did form) so it would not linger in the 
reaction mixture as much as it did when no acid was there. 
Scheme 2.3-4: KR of oxazinone (±)-II-1a in absence and presence of acid 
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Based on all these findings we proposed the mechanism of acid’s role in the process of 
asymmetric alcoholysis of N-acyl-β-lactams described in Figure 2.3-1.  
Figure 2.3-1: Proposed mechanism of acid’s role in alcoholysis of N-acyl-β-lactam II-3d 
 
 
 
 
 
 
 
 
 
In the set of conditions a (BTM I-3, PhCO2H, MeOH), the nucleophilic attack of BTM I-
3 would generate reactive intermediate II-18a (benzoate counterion omitted for clarity). 
Experimental results did suggest oxazinone II-1a formation, but we have reason to believe that 
the direction of equilibrium would be more towards the intermediate II-18a, since the amide 
moiety is not as nucleophilic in protonated form for subsequent cycloaddition. Even when 
oxazinone II-1a forms, it would be in activated form, which would become more susceptible to 
ring opening back to intermediate II-18a. It could also be that the rate of methanolysis was faster 
than that of forming the oxazinone II-1a. In the set of conditions b (BTM I-3, MeOH), the attack 
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of the catalyst would form the zwitterion II-18b, which possesses a nucleophilic amide moiety 
that could lead to the cyclized I-1a more readily than in the case of protonated intermediate II-
18a. Having witnessed experimentally a build-up of oxazinone I-1a in this case and a reduction 
in ester product II-2d’ formation might suggest a difference in rates of methanolysis and 
oxazinone II-1a formation. This scheme might hypothesize more on the mechanism of acid’s 
mode of action, but it does not explain how its addition helps/leads to a more enantioselective 
process. Showing an equilibrium between zwitterionic intermediate II-18b and oxazinone I-1a 
contradicts our initial statement that in the case of KR of oxazinone the first step in the catalytic 
cycle would be irreversible. At this point, it would be more cautious to say that the first step is 
just the enantioselectivity determining step in the case of KR of oxazinones, since no apparent 
improvement in selectivity was observed when bulkier alcohols were added instead of methanol. 
However, in the case of alcoholysis of N-acyl-β-lactams, the likelihood of reversibility in the 
first step in the catalytic cycle (attack of catalyst on the chiral acyl donor) is minimal, due to 
energetically disfavored formation of a strained 4-membered lactam ring under those set of mild 
conditions.   
As a result, this project was more complex and time-consuming than envisioned and 
additional tools, such as computational and more careful kinetic studies, are needed to untangle it 
- an investigation that prevails in the group’s future plans.  
2.4 Substrate synthesis 
Despite that racemic β-lactams have been mentioned in numerous studies, their synthesis 
to achieve a wide scope of substrates with decent yields was not a trivial matter. Hence, it is 
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noteworthy to discuss the methods that were used in making them and some of the challenges we 
have encountered while doing so.  
Racemic β-lactams can be obtained via three main approaches (Figure 2.4-1): 1) [2+2] 
reaction of olefins with clorosulfonyl isocyanate (CSI)4a,b,e (Eq. 1); 2) Enolate-imine 
cyclocondensation18 (Eq. 2); 3) Staudinger reaction ([2+2] reaction of ketenes generated in situ 
and imines) followed by CAN deprotection (Eq. 3).  
From all these methods, the one depicted in Eq. 1 was the most efficient, when 
conditions were previously reported for particular cases or established by trial and error in our 
lab. Substrates II-19, III-4 (see Chapter III), and all the cis-ring-fused β-lactams were generated 
by this method. However, the [2+2] cycloaddition of each substrate depended on different and 
special conditions: temperature (from 0 ºC to reflux at 80 ºC), reaction time (from 2 hours to 3 
days), solvent (neat, diethyl ether, methylene chloride, toluene). If one parameter was changed 
for optimization purposes, it raised the risk of obtaining little to no product at all. Hence, it was 
impossible to operate under one general procedure. Due to their similarity in structures, it was 
puzzling to us why their synthesis was so particular to each case. The enolate-imine 
cyclocondesation (Eq. 2) was an equally important route to obtaining the substrates (especially 
the ones used in Chapter III) we could not otherwise make using the one discussed in Eq. 1. The 
method, however, was not efficient and produced low yields of desired product with numerable 
undesired ones, making the purification process painful. Even though, at times, I had to repeat 
the procedure more than once just to obtain enough material for further processing, it was 
gratifying to have generated products not previously achieved under any other method. I did, 
however, fail to make the methyl- and o-methylphenyl-substituted β-lactams using this route.  
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Figure 2.4-1: Methods for β-lactam synthesis 
  
To extend the study on other substrates with practical utility, I intended to synthesize II-
20, II-21, and II-22 under method described in Eq. 3, having the starting materials readily 
available in our lab. In the case of II-20, the Staudinger reaction failed, despite trying two 
different protocols using the same starting materials19. In the cases of substrates II-216c,d,20 and 
II-2221, the Staudinger reaction itself occurred as previously described in the literature (with up 
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to 40% yield). The unreported deprotection with CAN of II-22 PMP-protected derivative was 
troublesome and, despite all efforts taken, I was not successful at obtaining the desired product 
II-22. The substrate II-21 was relevant to taxol synthesis6 and the reported CAN oxidation of its 
PMP-protected derivative did lead to II-21, although in disappointing yield overall. However, 
benzoylation of II-21 generated two compounds in 1:3 ratio. The one in least amount seemed to 
be the desired product. Unfortunately, I did not have enough material to be tested in the 
subsequent KR and had to repeat the whole synthesis again to obtain more substrate II-21. Due 
to unexpected difficulties encountered in the preparation of other substrates, this study of 
substrate scope was postponed, and we moved on to other pending projects that were seeking 
immediate attention.     
2.5    Conclusion 
The asymmetric alcoholysis of N-acyl-β-lactams with BTM has proven to be an effective 
method of obtaining enantioenriched β-amino acids. This transformation demonstrates for the 
first time that the nucleophilic attack of ABC on chiral acyl donors can in itself be highly 
enantioselective – a phenomenon in high contrast to the usual behavior of these catalysts. Cis 
ring-fused substrates display higher enantioselectivity. The plausible origin of enantioselectivity 
has been discussed/debated. Brønsted acid was necessary for higher enantioselectivity, but was 
not paramount to the occurrence of the KR. The mechanistic role of the acid in this 
transformation remains yet unclear and will be subject to further investigation in our group, 
along with extension of this mechanism to other classes of substrates.  
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Chapter III 
Kinetic Resolution of β-Lactams via Enantioselective N-Acylation 
using Amidine-based Catalysts 
 
3.1     Introduction 
β-Lactams have had a well-known application in pharmaceuticals (e.g. antibiotics1 and 
cholesterol lowering drugs2) and have been serving as versatile intermediates in the preparation 
of other classes of organic compounds (e.g. amino acids derivatives, nylon-3 polymers, etc.)3. 
Despite successfully accomplishing the asymmetric alcoholysis of N-acyl-β-lactams4 in our lab, 
the method does not generate enantioenriched β-lactams, since deprotection of the N-acyl-β-
lactam would cause ring opening. Asymmetric synthesis of β-lactams5 has been achieved by a 
number of groups, from which most promising results were attained by Fu et al using chiral 
DMAP-based catalyst6, Bode et al using NHC-based catalyst7, and Lectka et al using cinchona 
alkaloid derivative benzoylquinine8. However, in all those cases the substrate scope remained 
limited. Therefore, enzymatic kinetic resolution (KR)9 of their racemates, achieved via β-lactam 
ring opening10 or O-acylation of N-hydroxymethyl derivatives11, continues to be a viable 
approach to enantioenriched β-lactams (Scheme 2.1-1, Chapter II 2.1).  When β-lactams are 
available in racemic form, their nonenzymatic, catalytic KR can be accomplished directly via 
enantioselective N-acylation – a protocol that had not been established before.  
In 2006, our group became successful at resolving chiral oxazolidinones via asymmetric N-
acylation using ABCs.12 Before our work in this area, there were no reports of KR of any lactams 
via enantioselective N-acylation. Having racemic β-lactams available from KR of N-acyl-β-
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lactams, we wondered whether they were suitable substrates for asymmetric N-acylation and, 
hence, suitable nucleophiles for Type I process using our most efficient ABCs I-2 through I-4. 
3.2   Experimental design and findings 
While working on the KR of N-acyl-β-lactams, I also tried the enantioselective acylation of 
(±)-4-phenyl-β-lactam III-1 under the set of conditions established in our group in the successful 
catalytic, asymmetric N-acylation of oxazolidinones12 (Table 3.2-1). Disappointingly, BTM ent-
I-3 proved to be inept in this process as no reaction happened after 24 hours (entry 1). HBTM I-
4a did not show much superiority to ent-I-3 with only 10% conversion after 48 hours, despite its 
higher catalytic activity to previously developed catalysts in our lab (entry 2). Those results did 
not come as too surprising, since we thought that the pKa of the amide moiety would be too high 
to allow acylation.  Just when we were about to give up on the project, my labmate, Xing Yang, 
tried the acylation with Cl-PIQ I-2 and, to our delight, it gave promising results ( entry 3).  
Table 3.2-1: KR of β-lactam (±)-III-1: Catalyst screening 
    
 
 
General conditions: 0.1 M (±)-III-1, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.01 M catalyst in CDCl3. 
 
Entry Catalyst Time (hrs) Conv (%) s 
1 (S)-BTM ent-I-3 24 NR ND 
2 (S)-HBTM I-4a 48 ~10 ND 
3 (S)-Cl-PIQ ent-I-2 24 33 10 
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Encouraged by this finding and acquired experience in synthesizing many of the requisite 
substrates in the course of my earlier study (Chapter II), Xing and I started a collaboration. Xing 
continued with the optimization studies by varying the anhydride and the solvent (Table 3.2-2) 
and I began synthesizing additional substrates according to established procedures (see Figure 
2.4-1, Chapter II, 2.4) to be investigated after optimization was complete. The bulk of isobutyric 
anhydride proved to be crucial for notable selectivity (entry 1), since acetic and propionic 
anhydrides generated little to no enantioselectivity (entry 2 and 3). Methylene chloride and 
tetrahydrofuran produced lower selectivities compared to chloroform (entries 4,5 vs. 1). 
Switching to tert-amyl alcohol led to improved results both enantioselectivity and rate wise, 
despite a reduction in substrate concentration due to limited solubility (entry 6). Lowering the 
temperature to 0 °C enhanced the selectivity factor appreciably and the rate was still acceptable 
(entry 7). Lowering the catalyst or acylating agent/base loading only prolonged the rate of 
reaction and was considered impractical (entries 8, 9). Using 2-methyl-3-butyn-2-ol at room 
temperature led to similar results to tert-amyl alcohol (entry 10); however, due to its higher 
freezing point (+3 vs -12 °C) lowering the temperature to 0 ° would not be a viable route to 
increase enantioselectivity in this case. Therefore, tert-amyl alcohol became the solvent of 
choice. 
Table 3.2-2: KR of β-lactam (±)-III-1: Acyl donor and solvent screening 
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General conditions: 0.1 M (±)-III-1, 0.2 M (i-PrCO)2O, 0.2 M i-Pr2NEt, 0.01 M (S)-Cl-PIQ, unless otherwise 
specified. [a] 0.05 M (±)-III-1, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.005 M (S)-Cl-PIQ (10 mol%). [b] 0.05 M (±)-
III-1, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.0025 M (S)-Cl-PIQ (5 mol%). [c] 0.05 M (±)-III-1, 0.05 M (i-PrCO)2O, 
0.05 M i-Pr2NEt, 0.005 M (S)-Cl-PIQ (10 mol%). 
 
  With optimization conditions and most starting materials in place, Xing and I worked on 
the substrate scope together (Table 3.2-3). We explored a range of substrates bearing aryl, 
heteroaryl, and alkyl groups at C-4. Counterintuitively, both p-chloro- and p-methoxy-phenyl 
substituted substrates III-3 and III-4 gave higher selectivity compared to their phenyl-substituted 
analogue III-1 (entries 2,3 vs 1). The 2-naphthyl group led to the best results in this study (entry 
6). Having chlorine in the ortho position on the ring hindered the KR, as both rate and s-value 
diminished considerably (entry 4). The heteroaryl-substituted substrate III-8 underwent N-
acylation, albeit with lower enantioselectivity (entry 7). Additional alkyl groups at C-3 were 
tolerated, although both reaction times and selectivity factors were negatively affected (entries 8, 
Entry R Solvent Temp (°C) Time (hrs) Conv (%) s 
1 i-Pr (III-2a) CDCl3 23 24  33 10 
2 Me (III-2b) CDCl3 23 4 35 1.0 
3 Et (III-2c) CDCl3 23 10 35 1.8 
4 i-Pr (III-2a) CD2Cl2 23 24 21 5.5 
5 i-Pr (III-2a ) THF 23 24 22 6.6 
6a i-Pr (III-2a ) EtMe2COH 23 10 45 16 
7a i-Pr (III-2a ) EtMe2COH 0 24 47 20 
8b i-Pr (III-2a ) EtMe2COH 0 48 33 19 
9c i-Pr (III-2a ) EtMe2COH 0 24 35 21 
10a i-Pr (III-2a ) HC≡CMe2COH 23 10 41 16 
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9). All of the substrates discussed above were limited to bearing aryl (or heteroaryl) groups, as 
we expected that cation-π interactions with the catalyst would be crucial for the reaction to occur. 
In accord with this prediction, when the non-aryl substrate III-12 was subjected to the same 
conditions, it failed to react altogether (entry 11).     
 Table 3.2-3: KR of β-lactams: Substrate scope 
 
 
 
 
Entry Substratea,b Time (hrs) eePR (%) eeSM (%) Conv (%) s 
1 
III-1  
24 84 62.5 43 22 
2 
  
III-3 
30 79 94 54 30 
3 
 
III-4 
30 90 66 42 38 
4 
III-5 
30 48 8 14 3 
5c 
III-6  
72 83 57 41 19 
6 
   
30 85 97 53 54 
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III-7 
7 
III-8  
30 65 95 59 17 
8c 
III-9 
72 82 44 38 16 
9c 
                                
III-10 
72 81 28 26 13 
10 
III-11 
30 78 56 42 14 
11d 
III-12 
34 ND ND NR ND 
General conditions: 0.05 M (±)-substrate, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.01 M (S)-Cl-PIQ, tert-amyl alcohol, 
0 ºC, unless otherwise specified. [a] Absolute configuration of the fast reacting enantiomer is shown [b] Results 
based on duplicate runs. [c] 0.05 M (±)-substrate, 0.2 M (i-PrCO)2O, 0.2 M i-Pr2NEt, 0.01 M (S)-Cl-PIQ (10 mol%). 
[d] Reaction performed in CDCl3 at rt 0.05 M (±)-substrate, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.0025 M (S)-Cl-
PIQ (5 mol%).  
 
The absolute configuration of III-1 and of the indene-derived substrate III-11 was 
consistent with the results previously obtained with oxazolidinones and alcohols. Thus, we 
hypothesized that the TS for the catalytic N-acylation of β-lactams should be qualitatively 
similar to our previously proposed model for alcohols13 (Figure 1.1-1, Chapter I, 1.1). Indeed, a 
computational study later carried out by Xing14,15 produced TS structures TS-(R)-Cl-PIQ-(R)-
III-1 and TS-(R)-Cl-PIQ-(S)-III-1, which were in accordance with our predictions (Figure 3.2-
1).  
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Figure 3.2-1: Transition states for fast- and slow-reacting enantiomers of β-lactam III-1 
 
 
 
 
 
 
 
 
TS-(R)-Cl-PIQ-(R)-III-1                                                 TS-(R)-Cl-PIQ-(S)-III-1 
∆∆G‡= 0.0 kcal/mol                                                          ∆∆G‡= 3.4 kcal/mol 
3.3    Conclusions   
We have achieved the first non-enzymatic asymmetric KR of β-lactams via N-acylation 
using Cl-PIQ ent-I-2. The method requires the presence of aryl and heteroaryl substituted β-
lactams – a trend of ABCs consistent with other studied classes of compounds in our group (i.e. 
alcohols, oxazolidinones)16. Our experimental observations and computational studies point to 
the involvement of cation-π interactions between the fast-reacting enantiomer and catalyst, in 
analogy with alcohols and oxazolidinones. 
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Chapter IV 
Kinetic Resolution of N-Acyl-Thiolactams via Catalytic Enantioselective 
Deacylation 
 
4.1    Introduction 
Oxazoldine-2-thiones and thiazolidine-2-thiones thiolactams have had a wide application 
in organic synthesis as chiral auxiliaries,1 intermediates,2 and chiral reagents in resolution of 
other compounds.3 Some oxazoldine-2-thiones can be actually found in the structure of natural 
products that display biological activity.4 Asymmetric synthesis of above mentioned thiolactams 
is usually achieved from the reaction of their corresponding chiral β-amino alcohols with carbon 
disulfide,5 although β-amino thiols have also been used in synthesis of thiazolidine-2-thiones.6 
However, when the corresponding β-amino alcohols are not available in enantiopure form, the 
kinetic resolution7 (KR) of racemic thiolactams via asymmetric acyl transfer catalysis can serve 
as a practical protocol for obtaining them in enantioenriched form.      
In Chapter I, 1.1, we mentioned that that Type I and II processes are often 
complimentary and can be catalyzed by a single enzyme (Figure 1.1-2). So far, we have only 
witnessed considerable progress in Type I transformation using various acyl transfer asymmetric 
catalysts.8 However, to the best of our knowledge, the asymmetric deacylation (Type II process) 
of any classes of compounds using acylation catalysts has not been reported yet.9 In 1999, Yan et 
al reported a reverse action of achiral acyl-transfer catalyst DMAP in deacylation of N-acyl-
oxazolidine-2-thione via alcoholysis,10 followed by Wu et al with the same transformation of N-
acyl-thiazolidine-2-thione.11 Of course, both these processes were not enantioselective. Thus, this 
chapter describes the first instances of asymmetric deacylation using ABCs, providing also an 
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alternative method to obtaining enantioenriched oxazolidine-2-thiones and thiazolidione-2-
thiones via alcoholysis of their corresponding racemic N-acyl-derivatives.  
While working on the asymmetric acylation of lactams and thiolactams,12 Xing Yang 
subjected (±)-4-phenylthiozoline-2-thione IV-1 to standard acylating KR conditions13 with BTM 
I-3, which also included the quenching of excess anhydride with methanol when reaction 
reached 50% conversion by H1 NMR.  His initial results are shown in Scheme 4.1-1. However, if 
the quenched mixture stayed too long in the presence of methanol, then the conversion (and 
selectivity) dropped significantly, which was not in agreement with the one observed by H1 
NMR. We hypothesized that this could be a case where BTM I-3 participated also in the 
asymmetric deacylation (reverse reaction) of the enantioenriched N-acyl-thiozolidine-2-thione 
IV-2a, especially since we were aware that such a transformation has been previously reported 
with DMAP. These observations gave me the opportunity to step into this project and investigate 
the reverse process in more detail. 
Scheme 4.1-1: KR of thiazolodin-2-thione (±)-IV-1 via enantioselective N-acylation 
 
 
 
 
 
 
4.2    Experimental design and findings  
To test this presupposition, I preliminarily subjected crude racemic N-acyl-thiazolidine-2-thione 
IV-2a, which was contaminated with traces of isobutyric acid, to methanolysis in the presence of 
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BTM I-3. And to our surprise, the selectivity factor improved significantly (s = 88 vs 30), albeit 
at a slower rate (Scheme 4.2-1).  
 Scheme 4.2-1: Preliminary enantioselective deacylation of (±)-IV-2a 
 
 
 
 
 
Encouraged by these data, IV-2a was purified and the optimization process was initiated (Table 
4.2-1).  Interestingly, once the pure IV-2a was subjected to the KR conditions with MeOH and 
(R)-BTM I-3 the reaction was sluggish and led to diminished enantioselectivity (entry 2). We 
quickly realized that the traces of isobutyric acid were adventitious in the initial trial, and that the 
acid served as a co-catalyst. Introducing benzoic acid made the protocol more reproducible 
(entry 3). As expected, in the absence of a catalytic system, the background reaction was 
insignificant (entry 1). Testing other most effective catalysts from our group, Cl-PIQ I-2 and 
HBTM I-4a, led to disappointing results (entries 4, 5). Making sure that the nature of the alcohol 
in the deacylation did not play a role in the chiral recognition of IV-2a, methanol was exchanged 
for its more sterically hindered analogues, benzyl alcohol and di(1-naphthyl)methanol (entries 6, 
7). They delivered comparable results to methanol and, therefore, we continued with the 
optimization using the latter.     
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Table 4.2-1: KR of N-acyl-thiazolidine-2-thione (±)-4-5a: Catalyst and Alcohol screeninga 
 
 
 
 
 
 
General conditions: 0.05 mmol (±)-IV-2a, 0.075 mmol ROH, 0.01 mmol catalyst, 0.75 mL CDCl3, rt, unless 
otherwise specified. [a] Results averaged from duplicate runs. [b ]Determined by H1 NMR. [c] not determined 
 
Using I-3 as the catalyst of choice, we continued the optimization by varying the N-acyl group, 
then the solvent (Table 4.2-2). The bulkiness of the isopropyl group was crucial for increased 
enantioselectivity (entry 1), since N-propionyl-derivative delivered only a selectivity factor of 
15, although at a much faster rate (entry 2). Switching the N-acyl group to benzoyl stalled the 
reaction considerably (entry 3). Among solvents examined, methylene chloride and 
tetrahydrofuran were inferior to chloroform, as they gave diminished results (entries 4, 6), while 
Entry Catalyst ROH Time  Conv (%) s 
1 none MeOH 7 days <10a NDc 
2 (R)-BTM  MeOH 4 days 55 26 
3 (R)-BTM + 10 mol% PhCO2H MeOH 24 hrs 48 78 
4 (S)-HBTM + 10 mol% PhCO2H MeOH 7 days <10b NDc 
5 (R)-Cl-PIQ + 10 mol% PhCO2H MeOH 7 days 37 6.7 
6 (R)-BTM + 10 mol% PhCO2H PhCH2OH 24 hrs 49 81 
7 (R)-BTM + 10 mol% PhCO2H (1-Np)2CHOH 24 hrs 50 84 
53 
 
toluene was a bit superior to chloroform (entry 5). For convenience while monitoring the 
reaction by NMR we used the latter for the rest of this study.    
Table 4.2-2: KR of N-acyl-thiazolidine-2-thione (±)-IV-2: Solvent Screeninga 
 
 
 
 
General conditions: 0.05 mmol (±)-IV-2, 0.075 mmol MeOH, 0.01 mmol (R)-BTM, 0.75 mL solvent, rt. [a] Results 
based on duplicate runs. [b] Determined by H1 NMR. 
 
With the optimization process complete, we continued with investigation of substrate scope in 
the case of N-isobutyryl-thiazolidine-2-thiones (Table 4.2-3). The phenyl-substituted derivatives 
with electron-donating group (EDG) on the phenyl ring gave the best selectivities in this study, 
90 with p-methoxy- and 108 with o-methoxy (entries 2, 3). Having an electron-withdrawing 
group (EWG) on the phenyl ring led to significantly diminished enantioselectivities (entries 4, 
5). An interesting observation was that in both those cases, with EDG and EWG, ortho 
substituents gave notably higher results compared to the para ones. Switching R to 1- and 2-
Entrya R Solvent Time  Conv (%) s 
1 i-Pr (IV-2a) CDCl3 24 hrs 48 78 
2 Et (IV-2b) CDCl3 12 hrs 57 15 
3 Ph (IV-2c) CDCl3 7 days <10b ND 
4 i-Pr (IV-2a) CD2Cl2 24 hrs 49 41 
5 i-Pr (IV-2a) toluene 24 hrs 47 86 
6 i-Pr (IV-2a) diethyl ether 7 days 42 3.9 
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naphthyl, as well as with thienyl group, was no match in efficiency to the phenyl one in IV-2a, 
which was surprising considering that same groups displayed higher selectivities in the N-
acylation KR of analogous classes of compounds. Both substrates IV-10 and IV-11 underwent 
the KR, albeit with diminished results. However, they do play a more symbolic role since they 
are not aryl-substituted, but still contain extended π-systems. Any other attempt to expand the 
applicability of this method to other non-aryl substrates or other extended π-systems failed, as 
IV-12 did not react at all in the course of one week, and IV-13 gave insignificant selectivity. We 
had higher expectations for the indane-fused substrate IV-14, but its KR produced a 
disappointing s-value of 2.3. This was in contrast to the results in the N-acylation with Cl-PIQ I-
2 of indane-fused oxazolidin-2-one and β-lactam, which gave selectivities 36 and 14, 
respectively. To confirm that these results were not related to the nature of the deacylation 
process itself, the forward reaction of 4-18 (Scheme 4.2-2) was set up using previously set 
conditions for N-acylation of analogous compounds using Cl-PIQ 4-1 and BTM 4-212.  
Unfortunately, the results did not improve in either case.     
Table 4.2-3: KR of N-isobutyryl-thiazolidine-2-thiones: Substrate scopea 
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Entry Substratea Time 
(days) 
eePR 
(%) 
eeSM 
(%) 
Conv (%) s 
1 
IV-2a  
1 93 84 48 78 
2 
IV-3  
1 93.5 89 49 90 
3 
IV-4  
1 95 84 47 108 
4 
IV-5  
0.6 76.5 90 54 23 
5 
IV-6  
1 86 86 50 36 
6 
IV-7  
5 74.5 99 48 30 
7 
IV-8  
2 85 78 57 37 
8 
IV-9  
1.5 87 71 45 32 
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9 
IV-10  
1 88 77 47 37 
10 
IV-11  
0.6 75 73 49 15 
12 
IV-12  
7 ND ND NRb ND 
12 
IV-13  
7 15.5 6 27 1.4 
13 
IV-14  
7 32 16 33 2.3 
General conditions: 0.05 mmol (±)-substrate, 0.075 mmol MeOH, 10 mol% PhCO2H, 10 mol% (R)-BTM, in CDCl3, 
rt. [a] Results averaged from at least duplicate runs [a] Results averaged from duplicate runs [b] NR = no reaction 
 
Scheme 4.2-1: Enantioselective N-acylation of thiolactam (±)-IV-15 
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With study on N-isobutyryl-thiazolidine-2-thiones coming to an end, the investigation of KR of 
analogous N-isobutyryl-oxazolidin-2-thiones was only to begin (Table 4.2-4). Using the same 
study of optimized conditions established with N-isobutyryl-thiazolidine-2-thiones, a substrate 
scope started with KR of the N-isobutyryl-4-phenyl-oxazolidine-2-thione IV-16 (entry 1). The 
de-acylation of IV-16 gave what would be generally considered good selectivity factor of 57, 
although lower than in the case of the analogous thiazolidine-2-thione derivative IV-2a (s = 78) 
and than in the KR via N-acylation of corresponding oxazolidine-2-thione (s = 82). Additionally, 
the reaction time was longer than in the case of IV-2a. Despite the fact that the rest of the 
substrates gave increasingly sluggish rates and diminished enantioselectivities compared to the 
phenyl-substituted one, they had not been resolved before in our study of asymmetric N-
acylation and, hence, their KR represented practical merit based on their overall good 
selectivities in the range of 13 to 59, with the exception of IV-21. By analogy, we thought that an 
EDG on the phenyl substituent would positively affect the results and an EWG would impede 
them. However, the data were random and did not follow any particular trend (entries 2-5). The 
ester-derivative IV-21 underwent methanolysis slowly and with only a 2.6 s-value (entry 6). 
Surprisingly at first, in the case of IV-21 we observed that the apparent enantioselectivity 
plummeted with time (entry 6 vs. 7).   
Table 4.2-4: Asymmetric deacylation of N-isobutyryl-oxazolidin-2-thiones 
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Entry Substratea Time 
(days) 
eePR      
(%) 
eeSM    
(%) 
Conv (%) s 
1 
IV-16  
2 94 53 36 57 
2 
IV-17  
4 92 83 47 59 
3 
IV-18  
6 92 40 30 38 
4 
IV-19  
3 64 86 57 13 
5 
IV-20  
3 88 67 43 32 
6 
IV-21  
4 31 35 53 2.6 
7 
IV-21  
1 71 29 29 7.9 
General conditions: 0.05 mmol (±)-substrate, 0.075 mmol MeOH, 0.01 mmol (R)-BTM, 10 mol% PhCO2H, 0.75 mL 
CDCl3, rt. [a] Results averaged from at least duplicate runs  
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Hypothesizing that there might be a slow N-acyl exchange between deacylated product (R)-IV-
22 and (S)-IV-21 under the reaction conditions and, since the forward KR was accomplished 
faster, the N-acylation of 4-25 was performed and monitored over time by taking and analyzing 
aliquots by HPLC (Table 4.2-5). Our premises have been confirmed by experimental evidence, 
as indeed just 1.5 hours after which reaction reached 52% conversion and s of 17, the ees of both 
(R)-IV-21 and (S)-IV-22 deteriorated significantly to give a 7.5 selectivity factor. The process 
reached almost complete racemization after 48 hours.  
Table 4.2-5: Enantioselective acylation of thiolactam (±)-IV-22   
 
 
 
 
Entrya Time (hrs) ee% of (R)-IV-21 ee% of (S)-IV-22 Conv (%) s 
1 0.5 75 82 52 17 
2 1 57 62 48 7.5 
3 3 39 47 54 3.5 
4 8 33 36 52 2.8 
5 48 3.0 3.8 56 1.1 
General conditions: 0.05 mmol (±)-IV-22, 0.05 mmol i-Pr2NEt, 0.05 mmol (i-Pr2CO)2O, 0.0025 mmol (R)-BTM, 
0.5 mL CDCl3, rt. [a] Results averaged from duplicate runs 
To find the culprit in this N-acyl exchange, a control experiment was set up in which roughly 
equimolar amounts of enantioenriched (R)-IV-21 and (S)-IV-22 were mixed with 10 mol% of 
(R)-BTM I-3 in one vial and in separate vials with alternating additives that could be present 
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under the regular reaction condition (Hunig’s base, isobutyric acid) (Table 4.2-6). Unexpectedly, 
the results indicated that BTM I-3 was responsible for the N-acyl exchange, in the presence 
(entry 3) or absence (entry 2) of benzoic acid, as the ees deteriorated significantly after 24 hours. 
Other additives did not seem to have contributed to the racemization process (entries 4, 5).   
 Table 4.2-6: Racemization of IV-21 and IV-22     
 
Entry 
 
Additive(s) 
% ee after 24 hrs 
 (R)-IV-21 (S)-IV-22 
1 none 81 77 
2 10 mol% (R)-BTM I-3 18 14 
3 10 mol% (R)-BTM I-3 + 10 mol% PhCO2H 20 11 
4 50 mol% i-Pr2NEt 81 74 
5 10 mol% i-PrCO2H 82 75 
General conditions: 0.1 M (R)-IV-21, 0.1 M (S)-IV-22, additive(s), in CDCl3, rt.  
There is a chance that this exchange might have happened to some extent in the case of other 
substrates in this study, especially when the reaction times were long. Therefore, the 
experimentally shown selectivity factors could be lower than their “actual” ones.  
In proposing the origin of enantioselectivity, experimental data suggest that de-acylation of N-
acyl-thiolactams most probably goes through the same TSs as the “forward” (N-acylation) 
reaction of the corresponding thiolactams.  Thus, the chiral recognition of the former can be 
described by analogy by TSs obtained in computational studies of N-acylation of 4-
phenyloxazolidinone IV-26, performed by Xing Yang (Figure 4.2-1).12 The fast-reacting 
diastereomer TS-(R)-BTM-(S)-IV-26 is favored by 3.1 kal/mol due to π-cation interaction 
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between tziazolium moiety of the catalyst and the phenyl ring of the substrate, analogous to 
enantioselective acylation of alcohols. 
Figure 4.2-1: TSs of BTM-catalyzed N-acylation of oxazolidinone IV-26  
 
 
 
 
 
 
 
 
 
 
 
TS-(R)-BTM-(S)-IV-26                                                                    TS-(R)-BTM-(R)-IV-26 
∆∆G‡ = 0.0 kcal/mol                                                                         ∆∆G‡ = 3.1 kcal/mol 
                                                 
4.3    Conclusion 
We have demonstrated for the first time a catalytic asymmetric deacylation promoted by an acyl 
transfer catalyst. The asymmetric methanolysis of N-acyl-thiazolidine- and oxazolidine-2-thiones 
has been successfully accomplished with better enantioselectivities in the former case than the 
latter. The KR of N-acyl-thiazolidine-2-thiones produced better selectivity factors than in the 
forward N-acylation reaction of their deacylated derivatives and, hence, can be viewed as an 
alternative method for their enantioselective synthesis. There has been some evidence in one 
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investigated substrate case (although it could also be applicable to other substrates) of N-acyl 
exchange between enantioenriched products over prolonged time, promoted by the catalyst from 
the reaction mixture.  
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Chapter V 
Experimental Part 
 
 
5.1 General 
 All reagents and solvents were obtained commercially and used as received. Solvents used for 
HPLC were HPLC grade and for other purposes ACS grade. HPLC Analyses were performed on 
a Shimadzu LC system using Chiracel OD-H, Chiralpak AD and AD-H analytical chiral 
stationary phase columns (4.6x250 mm, Chiral Technologies, Inc.). Flash column 
chromatography was performed over ICN Echochrom silica gel (32-63μm). 1H and 13C NMR 
spectra were recorded on a Unity 300 MHz Varian spectrometer. High-resolution mass spectral 
analyses were performed at Washington Univerity MS Center on a Kratos MS-40TA 
spectrometer using Electro Spray Ionization (ESI) method. Infrared spectra were obtained from a 
Perkin-Elmer Spectrum Bx FTIR spectrophotometer using potassium bromide plates. Melting 
points were measured on a Mel-Temp II capillary melting point aparatus. The signs of optical 
rotation were determined in CHCl3 on a Rudolph Autopol III polarimeter.  
Catalysts BTM, Cl-PIQ, and HBTM were prepared as previously described.1 
Selectivity factors and % conversions were calculated using Kagan’s equations2: conversion C = 
eeSM/(eeSM+eePR)100%  and selectivity factor s = ln[(1—C)(1—eeSM)]/ln[(1—C)(1+eeSM)]), 
unless otherwise specified. 
 
1 a) Birman, V. B.; Li, X. Org. Lett. 2006, 8, 1351. b) Birman,V. B.; Jiang, H. Org. Lett. 2005, 7, 3445. c) 
Birman, V. B.; Li, X. Org. Lett. 2008, 10, 1115. 
2  Kagan, H. B.; Fiaud, J. C. Top. Stereochem. 1988, 18, 249. 
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5.2  KR OF N-ACYL-Β-LACTAMS VIA ENANTIOSELECTIVE ALCOHOLYSIS USING AMIDINE-BASED 
CATALYSTS 
5.2.1  General 
Refer to Chapter II for notation of compounds. Note: Recrystallization of BTM from 
Et2O/hexanes1 is recommended to ensure reproducible performance. Oxazinones II-1 and II-1a 
were prepared via a modification of a published procedure2 using DCC to effect the cyclization 
step. Racemic N-(p-nitrobenzoyl)- and N-(3,5-dinitrobenzoyl)-4-phenyl-azetidin-2-ones (see 
Table 5.2.2-3) were prepared via deprotonation of (±)-4-phenyl-azetidin-2-one with n-
butyllithium and acylation with the corresponding acyl chloride.3 All substrates II-3 through II-
13 were prepared via DMAP-catalyzed acylation of the corresponding racemic β-lactams.4 The 
precursors to substrates II-3 and II-7 through II-12 were obtained via cycloaddition of the 
corresponding alkenes with chlorosulfonyl isocyanate.5 The precursors to substrates II-5 and 2-
II-6 were synthesized from the corresponding aldehydes via condensation of their N-
(trimethylsilyl)imines with tert-butyl acetate Li enolate, according to a general procedure.6 The 
precursor to substrate II-13 was synthesized via dilithiation and alkylation of (±)-4-phenyl-
azetidin-2-one, as previously described.7 The substrates II-20, II-21, II-22 were attempted to be 
synthesized by Staudinger reaction, followed by deprotection with CAN, using previously 
reported procedures8,9,10.  
5.2.2  Kinetic Resolution experiments 
5.2.2.1 Optimization studies 
General procedure. To a solution of a racemic substrate (0.10 mmol) in 0.25 mL of CDCl3 was 
added 0.25 mL of a stock solution of 0.040 M (S)-BTM (0.010 mmol) and 0.040 M benzoic acid 
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(0.010 mmol) in CDCl3 followed by 0.25 mL of a 0.30 M solution of methanol in CDCl3 (0.075 
mmol). The reaction mixture was stirred magnetically at rt. Its progress was checked periodically 
by withdrawing aliquots, diluting them with CDCl3 and analyzing by 1H NMR. Upon reaching 
approximately 50% conversion, the reaction mixture was diluted with CH2Cl2, washed with 
water, dried over Na2SO4, concentrated, and separated by flash chromatography (silica gel, 
CH2Cl2, then CH2Cl2/EtOAc). Enantiomeric enrichment of the ester product and the unreacted 
starting material was determined by chiral stationary phase HPLC (for HPLC conditions, see 
individual compounds in Characterization Data and HPLC Propersties section 5.2.7). Each 
experiment was performed at least in duplicate, unless otherwise specified. The results compiled 
in following Tables in 5.2 section were obtained using variations of this basic protocol, as 
indicated. 
Table 5.2.2.1-1: KR of Oxazinone (±)-II-1: Survey of alcoholsa 
 
entry Alcohol # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 1-Np2CHOH 
1 35.3 30.82 46.61 2.77 
51 2.9 
2 33.62 42.04 55.56 2.86 
2 PhCH2OH 
1 39.9 60.36 60.2 4.4 
56 3.9 
2 40.82 45.18 52.53 3.62 
3 MeOH 
1 34.48 31.84 48.01 2.75 
48 3.3 
2 44.68 39.9 47.17 3.27 
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a) See General Procedure, except the substrate was dissolved in 0.5 mL of CDCl3 and 0.05 mmol 
of the alcohol indicated was used. 
 
Table 5.2.2.1-2: KR of N-benzoyl-β-Lactam (±)-II-3a: Survey of alcohols and catalystsa 
 
entry alcohol catalyst time # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 1-Np2CHOH (S)-BTM 68 h 
1 78.40 84.96 52.01 22.11 
51 21 
2 79.32 78.64 49.78 20.55 
2 PhCH2OH (S)-BTM 68 h 
1 72.01 88.70 55.36 17.5 
52 19 
2 80.44 75.88 48.54 20.92 
3 PhCH2OH (S)-BTM 48 h 
1 
2 
73.00 
72.68 
90.28 
90.58 
55.21 
55.56 
19.24 
18.41 
55 19b 
4 MeOH (S)-BTM 68 h 
1 66.70 96.14 59.04 18.94 
60 18 
2 60.94 97.66 61.58 17.13 
5 PhCH2OH (R)-Cl-PIQ 7 d 
1 31.88 21.36 40.12 2.36 
42 2.5c 
2 33.74 26.40 43.90 2.57 
6 MeOH (S)-HBTM 3 d 
1 56.84 90.48 61.42 10.73 
62 12c 
2 55.94 96.02 63.19 12.94 
a) See General Procedure, except the substrate was dissolved in 0.5 mL of CDCl3 and 0.05 mmol 
of the alcohol indicated was used. b) II-3a was dissolved in 0.5 mL of CDCl3, followed by 0.25 
mL of 0.04 M BTM (0.01 mmol), 0.25 mL of 0.2 M of PhCH2OH (0.05 mmol) in CDCl3, 2 mg 
LiBF4 (0.02 mmol) c) The absolute configuration of the product was inverted, in accord with that 
of the catalyst. 
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Table 5.2.2.1-3: KR of N-acyl-β-Lactams (±)-II-3: Survey of N-Acyl groups 
 
entry R1 time # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 t-BuO (II-3b) 7 d 
1 ND ND ND ND 
ND ND 
2 ND ND ND ND 
2 i-Pr (II-3c) 7 d 
1 ND ND ND ND 
ND ND 
2 ND ND ND ND 
3 4-ClC6H4 (II-3d) 20 h 
1 79.66 88.78 52.71 25.89 
53 26 
2 78.92 90.70 53.47 26.26 
4 4-NO2C6H4 (II-3e) 5 h 
1 75.34 87.80 53.82 20.2 
53 20 
2 76.46 83.88 52.31 19.52 
5a 4-NO2C6H4 (II-3e) 36 h 
1 79.34 78.42 49.71 20.49 
50 20 
2 78.46 76.64 49.41 18.98 
6 3,5-(NO2)2C6H4 (III-3f) 1 h 
1 20.46 52.68 72.03 2.38 
72 2.6 
2 23.76 60.14 71.68 2.76 
a) The reaction was conducted at 0 °C. 
 
Table 5.2.2.1-4: KR of N-acyl-β-Lactam (±)-II-3d: Survey of solventsa 
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entry solvent 
time 
d 
# 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 CD2Cl2 3.5 
1 74.72 89.30 54.44 20.40 
55 20.5 
2 73.38 91.76 55.56 20.66 
2b d8-toluene 7  
1 90.26 43.50 32.52 29.96 
38 29 
2 86.82 66.48 43.37 28.23 
3c CD3CN 3.5 
1 79.66 88.78 52.71 25.89 
53 26 
2 78.92 90.70 53.47 26.26 
4 d8-tetrahydrofuran 7 
1 75.34 87.80 53.82 20.2 
53 20 
2 76.46 83.88 52.31 19.52 
a) See General Procedure, except reaction was run in solvent of choice instead of CDCl3. b) II-3d 
precipitated out of solution almost immediately after reaction was started.  
 
Table 5.2.2.1-5: KR of N-acyl-β-Lactams: Substrate scopea 
 
entry substrate time # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 
 
22 h 
1 78.96 94.82 54.56 30.76 
55 30 
2 77.88 94.24 54.75 28.25 
        
2 
 
3 d 
1 93.74 84.42 47 83.07 
47 78 
2 93.06 83.46 47.28 73.12 
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3 
 
56 h 
1 96.0 89.9 48.36 151.2 
49 166 
2 96.21 93.38 49.25 180.1 
4 
 
24 h 
1 87.82 99.82 53.20 105.68 
53 111 
2 87.56 99.62 53.24 91.80 
3 89.72 99.80 52.66 125.10 
4 89.24 99.84 52.80 122.89 
5 
 
4 d 
1 
2 
96.84 
97.88 
80.42 
81.6 
45.37 
45.46 
154.79 
237.39 
45 196 
6 
 
7 d 
 
1 
2 
97.84 
98.58 
59.19 
58.94 
37.69 
37.42 
167.48 
255.06 
38 211 
7 
 
66 h 
1 
2 
95.34 
95.36 
94.22 
95.52 
49.70 
50.04 
150.97 
161.73 
50 156 
8 
 
32 h 
1 
2 
95.76 
99.16 
83.66 
80.02 
46.69 
45.52 
122.68 
125.94 
46 124 
9 
 
7 d 
1 
2 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND ND 
a) See General Procedure. 
 
5.2.2.2  Assignment of the absolute configuration 
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(a) The absolute configuration of the ester derived from substrate II-3a in the presence of (S)-
BTM was determined to be (R) on the basis of HPLC comparison with an enantioenriched 
sample of the same compound synthesized by acylation of authentic (+)-(R)-ester A.11  
(b) The unreacted substrate II-8 was determined to have the (1S, 2S) absolute configuration on 
the basis of HPLC comparison with an enantioenriched sample of the same compound 
synthesized by acylation of authentic (−)-(1R, 2R)-β-lactam B.12 
The absolute configurations of all other enantioenriched products were assigned by analogy with 
these two cases. 
5.2.2.3  Preparative-scale KR of N-acyl-β-lactam (±)-II-11 
 
A 50 mL round-bottom flask was charged with the racemic substrate II-11 (1.00 g, 3.62 mmol), 
Na2SO4 (~0.4 g), (R)-BTM (90.6 mg, 0.362 mmol), benzoic acid (45.2 mg, 0.362 mmol) and 27 
ml of dry CHCl3. Once the reactants dissolved, methanol (108 µL, 2.71 mmol) was added at 
once. The reaction progress was monitored by 1H NMR analysis of small aliquots of the reaction 
mixture. After 72 h, upon reaching ~50% conversion by 1H NMR, the reaction mixture was 
worked up with water. The organic phase was rotary evaporated and the crude residue was 
purified by flash chromatography on silica gel. The unreacted N-acyl-β-lactam (92.96% ee, 0.473 
g, 47% yield) and then the ester (95.23% ee, 0.491 g, 45% yield) were eluted with pure CH2Cl2.  
Further elution with 5% isopropanol and 1% triethylamine in CH2Cl2 was used to recover the 
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catalyst (0.083 g, 76% recovery). Conversion and s were calculated using Kagan’s equation to be 
49% and 140, respectively. 
5.2.2.4 Other modes of catalysis in KR of N-acyl-β-lactam (±)-II-11 
General Procedure: To a solution of a racemic substrate II-11 (0.05 mmol) in 0.25 mL of  
CDCl3 was added 0.25 mL of a stock solution of 0.040 M catalyst (0.010 mmol) and 0.15 M 
MeOH (0.0375 mmol) in CDCl3. See catalyst structures and notations in Chapter II, 2.3. The 
reaction mixture was stirred magnetically at rt. Its progress was checked periodically by 
withdrawing aliquots, diluting with CDCl3, and analyzing by 1H NMR. Upon reaching 
approximately 50% conversion, the reaction mixture was diluted with CH2Cl2 and separated by 
flash chromatography (silica gel, CH2Cl2, then CH2Cl2/EtOAc). Enantiomeric enrichment of the 
ester product and the unreacted starting material was determined by chiral stationary phase 
HPLC. Each experiment was performed at least in duplicate.  
Table 5.2.2.4-1: Other modes of catalysis in KR of N-acyl-β-lactam (±)-II-11 
 
entry Catalyst # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 II-14 
1 ND ND ND ND 
NRa ND 
2 ND ND ND ND 
2 II-15 
1 62.20 20.54 24.82 5.23 
47 4.2 
2 40.32 30.30 42.91 3.12 
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3 II-16 
1 48.64 40.22 45.26 4.22 
47 3.7b 
2 39.34 37.80 49.00 3.26 
4 II-16 
1 
2 
14.82 
10.88 
3.34 
7.96 
18.39 
42.25 
1.39 
1.34 
30 1.4c 
5 II-17 
1 
2 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
<10a ND 
6 II-18 
1 
2 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
NRa ND 
a) Determined by 1H NMR. b) General procedure was used, except toluene was used instead of 
CDCl3. c) General procedure was used, except acetonitrile was used instead of CDCl3. 
 
5.2.2.5 Study of acid role in KR of N-acyl-β-lactams 
 
Entries from Table 5.2.2.5-1, 5.2.2.5-2, 5.2.2.5-3, 5.2.2.5-4 will generally follow one of these 4 
procedures, unless otherwise specified. 
Procedure A:  To 0.05 mmol of substrate and Na2SO4 was added 0.2 mL of 0.025 M stock 
solution of (R)-BTM (10 mol%) in CDCl3, followed by 0.175 mL of stock solution of 0.21 M of 
methanol (0.0375 mmol) in CDCl3. Sample runs were analyzed and processed as described in 
any other procedure from above. 
Procedure B: To 0.05 mmol of substrate was added 0.1 mL of 0.05 M stock solution of (R)-
BTM (10 mol%) in CDCl3 and 0.1 mL of 0.05 M benzoic acid (10 mol%) in CDCl3, followed by 
0.175 mL of stock solution of 0.21 M of MeOH (0.0375 mmol) in CDCl3. Sample runs were 
analyzed and processed as described in any other procedure from above. 
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The following stock solutions have been made for Procedures C and D: 1) Stock Solution A: 
114.24 g, 8 mmol of 2-7d and 60.8 mg, 8 mmol of 2,6-methoxy-toluene (8 mmol) were 
dissolved in 1.6 mL CDCl3. 2) Stock Solution B: 10 mg, 0.8 mmol of (R)-BTM and 12 mL of 
methanol were dissolved in 0.8 mL of CDCl3. 2) Stock Solution C: 2.5 mg, 0.4 mmol of benzoic 
acid was dissolved in 0.3 mL of CDCl3.  
Procedure C: To Vials #1 and #2 0.2 mL of Stock Solution A, 0.2 mL of Stock Solution B, 75 
μL CDCl3, and Na2SO4 were added. To Vial #3 was added double the amounts of solutions 
added in Vial #1, 2. Aliquots were removed exclusively from Vial #3 for 1H NMR analysis. 
After 14 hours, the reaction mixture from vial #1, 2 were diluted with CH2Cl2 and separated by 
flash chromatography (silica gel, CH2Cl2, then CH2Cl2/EtOAc). Enantiomeric enrichment of the 
products and the unreacted starting material was determined by chiral stationary phase HPLC.  
Procedure D: To Vials #1 and #2 0.2 mL of Stock Solution A, 0.2 mL of Stock Solution B, 75 
μL Stock Solution C, and Na2SO4 were added. To Vial #3 was added double the amounts of 
solutions added in Vial #1, 2. Aliquots were removed exclusively from Vial #3 for 1H NMR 
analysis. After 22 hours, the reaction mixtures from vial #1, 2 were diluted with CH2Cl2 and 
separated by flash chromatography (silica gel, CH2Cl2, then CH2Cl2/EtOAc). Enantiomeric 
enrichment of the products and the unreacted starting material was determined by chiral 
stationary phase HPLC.  
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Table 5.2.2.5-1: Testing the catalytic system in the KR of N-acyl-β-lactam (±)-II-3d 
 
 
 
entry 
Additive Time 
h 
# 
eeester 
% 
eeβ-lac 
% 
eeox 
 
CHPLC 
% 
s 
1a (R)-BTM 
 1 66.82 92.96 NDb 58.03 16.52 
24  2 
3 
68.06 
64.98 
93.19 
93.46 
87.52 
87.60 
NA 
NA 
NA 
NA 
2b (R)-BTM + PhCO2H 24  1 82.79 82.86 ND 50.02 27.30 
3d (R)-BTM + PhCO2H 24  1 81.04 89.60 ND 52.51 28.68 
4e none 24  1 ND ND ND NRf ND 
5g 2,4,6-collidine 48  1 ND ND ND 15f ND 
a) Procedure A was followed b) Decomposed on column. c) Procedure B was followed, except 
0.05 mmol of 2,6-methoxytoluene was also added and 0.1 mL of 0.1 M benzoic acid was used 
instead of 0.05 M. d) Procedure B was followed, except 0.05 mmol of 2,6-methoxytoluene was 
added also and 0.1 mL of 0.25M of benzoic acid was used instead 0.05 M. e) to 0.05 mmol II-3d 
was added 0.375 mL of 0.1 M solution of methanol in CDCl3 g) To 0.05 mmol of II-3d  was 
added 0.05 mmol of 2,4,6-collidine  and 0.375 mL of 0.1 M solution of methanol in CDCl3 f) 
Determined by 1H NMR 
 
Table 5.2.2.5-2: KR of N-acyl-β-lactam (±)-II-3d to obtain enantiopure oxazinone (±)-II-1a 
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entry 
Catalyst/ 
Additive 
Time 
h 
# 
eeβ-lac 
% 
eeox 
% 
CHPLC 
% 
s 
1a none  24  1 55.00 90.50 37.80 34.82 
2b 10 mol% PhCO2H 24  1 36.68 93.84 28.10 45.06 
a) Procedure A was followed, except II-3d was dissolved in 0.175 mL CDCl3 and no methanol 
was added. b) Procedure B was followed, except II-3d was dissolved in 0.175 mL CDCl3 and no 
methanol was added. 
 
Table 5.2.2.5-3: KR of oxazinone (±)-II-1a in presence and absence of acid 
 
 
entry Additive # 
eePR 
% 
eeSM 
% 
CHPLC 
% 
s 
CAVG 
% 
sAVG 
1 none 
1 45.52 39.84 46.67 3.87 
48 3.8 
2 43.50 41.14 48.61 3.72 
2 10 mol% PhCO2H 
1 
2 
36.38 
34.54 
44.26 
48.04 
54.89 
51.88 
3.21 
2.89 
53 3.0 
a) Procedure A was followed. b) Procedure B was followed. 
 
Table 5.2.2.5-4: Monitoring formation of products in KR of N-acyl-β-lactam (±)-II-3d in 
presence and absence of acid 
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entry Additive # 
eeester 
% 
eeβ-lac 
% 
eeox CHPLC 
% 
s 
CAVG 
% 
sAVG 
1a none 
1 75.62 63.02 
65.80 Cox=19b
Cester=13b 
sox=6c 
sester=8c NA NA 
2 77.84 65.86 NDd NA NA 
2e 
10 mol% 
PhCO2H 
1 
2 
83.02 
81.32 
86.82 
88.10 
NDd 
NDd 
51.12 
52.00 
30.20 
28.01 
51.5 29 
      Time  without PhCO2Ha With 10 mol% PhCO2OHc 
Entry  β-lactam 
used (%) 
Ester formed 
(%) 
Oxazinone 
formed (%) 
β-lactam 
used (%) 
Ester formed 
(%) 
Oxazinone 
formed (%) 
1 0.5 hrs <2 <1 <1 3 < 1  < 1 
2 1 hrs 14 8 5 4 5 < 1 
3 2 hrs 14 8 5 8 8 < 1 
4 4 hrs 25 13 7 17 12 < 3 
5 6 hrs 37 13 12 24 19 < 1 
6 8 hrs 38 13 14 31 19 < 3 
7 10 hrs 39 13 17 34 24 < 1 
8 12 hrs 44 13 19 39 29 < 1 
a) Procedure C was followed. b) % Conv was determined by 1H NMR. c) S-value was calculated 
using Kagan's alternative equation: s = ln[1-C(1+eePR)]/ln[1-C(1-eePR)] d) Not enough material 
for analysis. e) Procedure D was followed. 
  
5.2.3 Preliminary Computational Studies on KR of N-acyl-β-lactams 
The proposed transition states for fast and slow reacting enantiomers were located under DFT 
B3LYP/3-21G(d) level calculations. The TSs were constructed under the following assumptions: 
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A. BTM attacks the acyl carbonyl from the less hindered face of the substrate. 
B.  The acyl carbonyl is nearly coplanar with the benzothiazolium moiety and points towards the 
sulfur atom (S-O interaction).  
 
 
 
 
TS-(S)-BTM-(R)-II-3a                                                
 
 
 
 
 
 
 
 
 
 
 
 
E(RB3LYP) = -1899.08581450 a.u. 
# opt=(calcfc,ts,noeigen,maxstep=5) freq=noraman b3lyp/3-21g* geom=con 
 nectivity 
Symbolic Z-matrix: 
 Charge =  0 Multiplicity = 1 
 N                    -0.6049    0.50576  -0.3496  
 C                    -1.82114   0.19323  -0.71113  
 N                    -2.80354   0.75481   0.05797  
 S                    -2.4269   -0.81966  -1.98744  
 C                    -4.10514   0.47792  -0.35991  
 C                    -4.09098  -0.36289  -1.495  
 C                    -5.28298  -0.76787  -2.08149  
 H                    -5.27839  -1.41508  -2.95059  
 C                    -5.30591   0.91803   0.18974  
 H                    -5.31407   1.56166   1.06031  
 C                    -6.5003    0.50795  -0.40887  
 H                    -7.44323   0.84193   0.00648  
 C                    -6.4919   -0.32529  -1.5324  
 H                    -7.42744  -0.6322   -1.98324  
 C                    -2.20928   1.58173   1.13792  
 H                    -2.43895   2.63882   0.98396  
 H                    -2.56457   1.25456   2.1172  
 C                    -0.65843   1.29446   0.95494  
 H                    -0.31151   0.62411   1.74264  
 C                     0.66136  -0.34422  -1.14111  
 O                     0.11142  -1.26282  -1.83162  
 N                     1.6482   -0.59811   0.03525  
 C                     1.68025   0.73451  -1.65486  
 H                     2.05578   0.483    -2.64617  
 H                     1.29902   1.75283  -1.60664  
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 C                     2.66554   0.36804  -0.48961  
 C                     1.57086  -0.96999   1.35338  
 O                     2.32396  -0.45677   2.21895  
 C                     0.52824  -1.97413   1.74051  
 C                    -0.24531  -2.69708   0.8219  
 C                     0.37402  -2.19919   3.11598  
 C                    -1.18117  -3.62185   1.29259  
 H                    -0.12738  -2.52325  -0.24406  
 C                    -0.55797  -3.12344   3.57822  
 H                     1.01285  -1.64191   3.79009  
 C                    -1.34088  -3.83673   2.66383  
 H                    -1.78167  -4.18105   0.58397  
 H                    -0.67153  -3.29598   4.64247  
 H                    -2.0655   -4.56106   3.01921  
 C                     0.19369   2.5461    0.93349  
 C                     1.31486   2.63003   1.77012  
 C                    -0.11927   3.61891   0.0867  
 C                     2.09448   3.79051   1.77802  
 H                     1.61144   1.76695   2.35861  
 C                     0.66286   4.77346   0.095  
 H                    -0.96792   3.54817  -0.58606  
 C                     1.76677   4.86443   0.94905  
 H                     2.96084   3.84826   2.42651  
 H                     0.41592   5.59829  -0.56317  
 H                     2.37192   5.76346   0.95809  
 H                     2.86224   1.18206   0.20678  
 C                     3.9397   -0.30824  -0.9405  
 C                     5.18216   0.29909  -0.73455  
 C                     3.88239  -1.53925  -1.61083  
 C                     6.35401  -0.30596  -1.19684  
 H                     5.23351   1.24519  -0.2055  
 C                     5.05084  -2.143    -2.07221  
 H                     2.91638  -2.00771  -1.76347  
 C                     6.2908   -1.52825  -1.86727  
 H                     7.31202   0.17297  -1.02814  
 H                     4.99745  -3.09462  -2.58904  
 H                     7.19853  -2.00149  -2.22404  
 
 
                                                                           
 
 
 
  TS-(S)-BTM-(S)-II-3a 
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E(RB3LYP) = -1899.07750226 a.u. 
# opt=(calcfc,ts,noeigen,maxstep=5) freq=noraman b3lyp/3-21g* geom=con 
 nectivity 
Symbolic Z-matrix: 
 Charge =  0 Multiplicity = 1 
 N                     0.78822  -0.024    -0.91228  
 C                     1.97146  -0.5391   -0.6707  
 N                     3.01782   0.26119  -1.0347  
 S                     2.45671  -2.07136  -0.01481  
 C                     4.28266  -0.26507  -0.76681  
 C                     4.16787  -1.55174  -0.19816  
 C                     5.30791  -2.2698    0.1408  
 H                     5.22777  -3.25868   0.57678  
 C                     5.52869   0.31156  -0.99566  
 H                     5.61222   1.29991  -1.42983  
 C                     6.66944  -0.41716  -0.64901  
 H                     7.64746   0.01639  -0.81829  
 C                     6.56287  -1.69412  -0.08706  
 H                     7.45836  -2.24327   0.17625  
 C                     2.51795   1.55854  -1.5509  
 H                     2.69173   2.35277  -0.8201  
 H                     2.97973   1.80837  -2.50793  
 C                     0.96371   1.26825  -1.69532  
 H                     0.72338   1.05371  -2.74196  
 C                    -0.52706  -1.07904  -0.68813  
 O                    -0.04417  -2.12661  -0.11553  
 N                    -1.64114  -0.23477  -0.08281  
 C                    -1.35326  -1.05903  -2.03366  
 H                    -0.8949   -0.49516  -2.8465  
 H                    -1.61614  -2.06656  -2.35248  
 C                    -2.51364  -0.30368  -1.29265  
 H                    -2.76323   0.682    -1.68939  
 C                    -3.74596  -1.15843  -1.08506  
 C                    -4.99545  -0.7528   -1.56023  
 C                    -3.62654  -2.39913  -0.43858  
 C                    -6.11492  -1.57494  -1.40476  
 H                    -5.09587   0.21349  -2.04338  
 C                    -4.74304  -3.21825  -0.28313  
 H                    -2.65412  -2.70684  -0.06666  
 C                    -5.99083  -2.80984  -0.76701  
 H                    -7.08056  -1.24779  -1.77366  
 H                    -4.64352  -4.17451   0.21811  
 H                    -6.8582   -3.44811  -0.64216  
 C                    -2.02876   0.42247   1.06534  
 O                    -3.06181   1.12173   1.05351  
 C                    -1.18697   0.31185   2.30149  
 C                    -0.20396  -0.66325   2.50818  
 C                    -1.47662   1.23648   3.31566  
 C                     0.50414  -0.68169   3.71351  
 H                    -0.0245   -1.40887   1.73877  
 C                    -0.76473   1.21797   4.51099  
 H                    -2.27751   1.94278   3.13416  
 C                     0.23474   0.2585    4.71039  
 H                     1.26141  -1.44067   3.87623  
 H                    -0.99078   1.93717   5.29026  
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 H                     0.78891   0.23738   5.64236  
 C                     0.12749   2.42615  -1.20291  
 C                    -0.48406   3.27869  -2.12937  
 C                     0.01165   2.69565   0.16529  
 C                    -1.1975    4.39773  -1.6933  
 H                    -0.40612   3.06718  -3.19132  
 C                    -0.71324   3.80381   0.59941  
 H                     0.44176   2.01349   0.8878  
 C                    -1.31221   4.66161  -0.32771  
 H                    -1.66983   5.05207  -2.41654  
 H                    -0.82401   3.98461   1.6615  
 H                    -1.87829   5.51997   0.01392  
 
5.2.4  Characterization data and HPLC properties. 
Note: Melting points and spectral data were determined using racemic samples. The absolute 
configuration, where indicated, corresponds to the major enantiomer produced using (S)-BTM. 
 
Known compound.1 1H NMR (300 MHz, CDCl3): δ 8.15 (m, 2H), 7.55-7.26 (m, 
8H), 5.07 (dd, J1= 11 Hz, J2= 5 Hz, 1H), 3.06 (dd, J1= 16 Hz, J2= 5 Hz, 1H), 2.68 
(dd, J1= 16 Hz, J2= 11 Hz, 1H); HPLC (CHIRALCEL OD-H, 
hexane/isopropanol 10:1, 1 mL/min): 11.1 min (minor); 12.3 min (major). 
 
White solid; 1H NMR (300 MHz, CDCl3): δ 8.04 (d, J= 8.5 Hz, 2H), 7.43-7.25 
(m, 7H), 5.02 (dd, J1= 11.4 Hz, J2= 5.0 Hz, 1H), 3.04 (dd, J1= 16.1 Hz, J2= 5.0 
Hz, 1H), 2.64 (dd, J1= 16.1 Hz, J2= 11.4 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 
165.25, 152.85, 140.41, 138.35, 129.24, 128.98, 128.84, 128.77, 127.99, 126.22, 
56.57, 36.09; IR  (KBr, cm-1): 1792, 1672, 1603, 1585, 1492, 1449, 1274, 1198, 1135; MS: HR-
ESI calculated for [(C16H12ClNO2)+H]+: 286.0557, found: 286.0638; HPLC (CHIRALCEL AD-
H, hexane/isopropanol 100:1, 1 mL/min): 31.2 min (major); 36.8 min (minor).  
 
 
Known compound.3,4b 1H NMR (300 MHz, CDCl3): δ 8.02 (d, J=6 Hz, 2H), 
7.63-7.57 (m, 1H), 7.51-7.31 (m, 7 H), 5.30 (dd, J1= 6 Hz, J2= 3 Hz, 1H), 3.53 
(dd, J1= 15 Hz, J2= 6 Hz, 1H), 3.10(dd, J1= 15 Hz, J2= 3 Hz, 1H); HPLC 
(CHIRALPAK AD, hexane/isopropanol 100:1, 1 mL/min): 52.5 min (minor); 
82.2 min (major). 
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White solid; mp: 204-206 °C; 1H NMR (300 MHz, CDCl3): δ 8.35 
(s,1H), 7.90-7.75 (m, 6H), 7.66 (d, J= 7.1, 2H), 7.56-7.26 (m, 14H), 
7.2 (d, J= 7.1 Hz, 1H), 7.05 (d, J= 7.1 Hz, 1H), 5.70 (m, 1H), 3.26 
(dd, J1= 15.9 Hz, J2= 5.0 Hz, 1H), 3.12 (dd, J1= 15.9 Hz, J2= 5.0 
Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 171.2, 166.7, 140.5, 134.5, 134.3, 134.2, 134.1, 134.0, 
131.8, 131.1, 129.4, 129.2, 129.1, 129.0, 128.8, 127.9, 127.2, 127.1, 126.5, 126.2, 126.1, 126.0, 
125.9, 125.5, 123.3, 71.8, 49.8, 40.0; IR (KBr, cm-1): 3312, 3060, 1735, 1638, 1532, 1511; MS: 
HR-ESI calculated for [2(C37H29NO3)+H]+: 1071.4368, found: 1071.4410; HPLC 
(CHIRALCEL OD-H, hexane/isopropanol 4:1, 1 mL/min): 11.1 min (minor); 14.6 min (major); 
sign of rotation: (+). 
 
White solid; mp: 138-141 ºC; 1H NMR (300 MHz, CDCl3): δ 7.80 (d, 
J= 8.3 Hz, 2H), 7.51-7.19 (m, 13H), 5.70-5.63 (m, 1H); 5.10 (d, J= 
12.1 Hz, 1H), 5.04 (d, J= 12.1 Hz, 1H), 3.11 (dd, J1 = 15.7 Hz, J2 = 
5.5 Hz, 1H), 3.00 (J1 = 15.7 Hz, J2 = 5.5 Hz, 1H);  13C NMR (75 
MHz, CDCl3): δ 171.6, 166.7, 140.6, 135.5, 134.4, 131.9, 129.0, 128.8, 128.6, 128.5, 127.9, 
127.3, 126.5, 66.9, 50.0, 40.2; IR (KBr, cm-1): 3435 (br), 2094 (br), 1732, 1637, 1530, 1489; 
MS: HR-ESI calculated for [(C23H21NO3)+H]+: 360.1594, found: 360.1586; HPLC 
(CHIRALCEL OD-H, hexane/isopropanol 4:1, 1 mL/min): 9.4 min (minor); 14.3 min (major). 
 
Known compound.13 1H NMR (300 MHz, CDCl3): δ 7.84 (d, J=7 Hz, 2H), 
7.54-7.26 (m, 8H), 5.64 (m, 1H), 3.64 (s, 3H), 3.10-2.93 (m, 2H); HPLC 
(CHIRALCEL OD-H, hexane/isopropanol 10:1, 1 mL/min): 7.3 min 
(minor); 9.7 min (major). 
 
Known compound.4a 1H NMR (300 MHz, CDCl3): δ 7.36 (m, 5H), 4.93 (dd, 
J1= 6 Hz, J2= 3 Hz, 1H), 3.44 (dd, J1= 15 Hz, J2= 3 Hz, 1H), 2.92 (dd, J1= 16 
Hz, J2= 3 Hz, 1H), 1.38 (s, 9H). 
 
White solid; mp: 95-97 °C; 1H NMR (300 MHz, CDCl3): δ 7.39-7.28 (m, 
5H), 5.02 (dd, J1 = 9.9 Hz, J2 = 3.3 Hz, 1H), 3.53 (dd, J1=16.2, J2= 6.6 Hz, 
1H), 3.41 (m, 1H), 2.97 (dd, J1= 16.2 Hz, J2= 3.3 Hz, 1H), 1.25 (d, J=7.1 
Hz, 3H), 1.17 (d, J=7.1Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.1, 
165.1, 138.3, 129.2, 128.6, 125.9, 52.2, 45.5, 35.1, 19.1, 17.8; IR (KBr, 
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cm-1): 2973, 1775, 1697, 1285, 1253; MS: HR-ESI calculated for [(C13H15NO2)+H]+: 218.1176, 
found: 218.1175.  
 
White solid; mp: 117-120 °C; 1H NMR (300 MHz, CDCl3): δ 7.99 (d, 
J=9.1 Hz, 2H), 7.47-7.30 (m, 7H), 5.29 (dd, J1= 6.9 Hz, J2= 3.8 Hz, 
1H), 3.58 (dd, J1= 16.2 Hz, J2= 6.9 Hz), 3.14 (dd, J1= 16.2 Hz, J2= 3.6 
Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 164.9, 164.4, 140.1, 138.3, 
131.7, 130.5, 129.2, 128.9, 128.8, 126.3, 52.1, 44.7; IR (KBr, cm-1): 3436 (br), 1790, 1674, 
1310; MS: HR-ESI calculated for [(C16H12ClNO2)+H]+: 286.0629, found: 286.0628; HPLC 
(CHIRALCEL OD-H, hexane/isopropanol 4:1, 1 mL/min): 12.2 min (major); 16.4 min (minor); 
sign of rotation: (−). 
 
White solid; mp: 124-129 °C; 1H NMR (300 MHz, CDCl3): δ 7.79 
(d, J= 8.8 Hz, 2H), 7.59 (d (br), J= 8.0 Hz, 1H), 7.42 (d, J= 8.8 Hz, 
1H), 7.34-7.29 (m, 5H), 5.60 (m, X from ABX pattern, 1H), 3.64 (s, 
1H), 3.07-2.91 (dd, AB from ABX pattern, J1= 16.0 Hz, J2=  5.5 Hz, 
2H); 13C NMR (75 MHz, CDCl3): δ 172.4, 165.7, 140.6, 138.1, 132.8, 129.1, 129.0, 128.7, 
127.9, 126.4, 52.2, 50.1, 39.7; IR (KBr, cm-1): 3435 (br), 2100 (br), 1636; MS: HR-ESI 
calculated for [C17H16ClNO3+H]+: 318.0891, found: 318.0890; HPLC (CHIRALCEL OD-H, 
hexane/isopropanol 4:1, 1 mL/min): 11.1 min (major); 12.6 min (minor); sign of rotation: (−).  
 
White solid; mp:138-140 °C; 1H NMR (300 MHz, CDCl3): δ 8.34 (d, 
J= 8.8 Hz, 2H), 8.17 (d, J= 8.8 Hz, 1H), 7.44-7.36 (m, 5H), 5.32 (dd, 
J1= 6.9 Hz, J2= 3.8 Hz, 1H), 3.64 (dd, J1= 16.5 Hz, J2= 6.9 Hz, 1H), 
3.21 (dd, J1= 16.5 Hz, J2= 3.8 Hz, 1H);  13C NMR (75 MHz, CDCl3): 
δ 164.5, 161.7, 148.5, 137.1, 135.5, 130.1, 129.4, 129.3, 126.5, 122.7, 53.0, 45.3; IR (KBr, cm-
1): 3435 (br), 2099 (br), 1793, 1675, 1524, 1311; MS: HR-ESI calculated for 
[(C16H12N2O4)+Na]+: 319.0695, found: 319.0712; HPLC (CHIRALPAK AS-H, 
hexane/isopropanol 4:1, 0.8 mL/min): 21.6 min (major); 31.1 min (minor); sign of rotation: (−). 
 
White solid; mp:136-138 °C; 1H NMR (300 MHz, CDCl3): δ 8.30 
(d, J= 8.5 Hz, 2H), 8.01 (d, J = 9.1 Hz, 2 H), 7.81(d (br), J= 8.3 
Hz, 1H), 7.37-7.27 (m, 5H), 5.61 (m, X from ABX pattern, 1H), 
3.67 (s, 3H), 3.01 (AB from ABX pattern, J1= 16.0 Hz, J2= 5.5 Hz,  
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2H); 13C NMR (75 MHz, CDCl3): δ 172.5, 164.7, 149.9, 140.2, 139.9, 129.1, 128.5, 128.2, 
126.4, 124.1, 52.3, 50.4, 39.5; IR (KBr, cm-1): 3435 (broad), 2092 (broad), 1643, 1525, 1345; 
MS: HR-ESI calculated for [(C16H14N2O5)+H]+: 329.1132, found: 329.1126; HPLC 
(CHIRALCEL OD-H, hexane/isopropanol 4:1, 0.8 mL/min): 31.9 min (major); 58.3 min 
(minor); sign of rotation: (−). 
 
White solid; mp: 157-159 °C; 1H NMR (300 MHz, CDCl3):, δ 9.26 
(app. t, J = 2.1 Hz, 1H); 9.17 (app. d, J = 2.2 Hz, 2H), 7.45-7.38 (m, 
5H), 5.37 (dd, J1= 6.6 Hz, J2= 3.9 Hz, 1H), 3.72 (dd, J1= 16.8 Hz, J2= 
6.6 Hz, 1H), 3.32 (dd, J1= 16.8 Hz, J2= 3.9 Hz); 13C NMR (75 MHz, 
CDCl3): δ 164.4, 164.1, 150.6, 137.8, 137.6, 131.2, 129.3, 128.9, 
126.3, 123.5, 52.6, 45.1; IR (KBr, cm-1): 3435 (broad), 2100 (broad), 1797, 1630, 1542, 1345, 
1311; MS: HR-ESI calculated for [(C16H11N3O6)+Na]+: 364.0546, found: 364.0554; HPLC 
(CHIRALPAK AS-H, hexane/isopropanol 4:1, 0.8 mL/min): 40.2 min (major); 59.9 min 
(minor). 
 
White solid; mp: 184-188 °C; 1H NMR (300 MHz, CDCl3): δ 
9.18 (t, J= 1.9 Hz, 1H), 8.99 (d, J= 1.9 Hz, 2H), 8.03 (d (br), J= 
8.0 Hz, 1H), 7.83-7.30 (m, 5H), 5.62 (m, X from ABX pattern, 
1H), 3.69 (s, 3H), 3.11-2.97 (dd, AB from ABX pattern, J1= 16.0 
Hz, J2=5.5 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 172.4, 162.2, 
148.9, 139.8, 137.9, 129.2, 128.4, 127.5, 126.4, 121.4, 52.5, 50.9, 39.3; IR (KBr, cm-1): 3434 
(broad), 2092 (broad), 1642, 1540, 1344; MS: HR-ESI calculated for [(C17H15N3O7)+Na]+: 
396.0802, found: 396.0793; HPLC (CHIRALPAK AS-H, hexane/isopropanol 4:1, 1 mL/min): 
23.6 min (major); 35.8 min (minor). 
 
White solid; mp: 181-183 °C; 1H NMR (300 MHz, CDCl3): δ 8.1 
(d, J= 8.3 Hz, 2H), 7.94-7.82 (m, 3H), 7.61-7.41 (m, 6H), 6.01 
(dd, J1= 6.3 Hz, J2= 4.1 Hz, 1H), 3.78 (dd, J1= 16.2 Hz, J2= 6.6 
Hz, 1H), 3.04 (dd, J1= 16.2 Hz, J2= 4.0 Hz, 1H); 13C NMR (75 
MHz, CDCl3): δ 165.4, 164.3, 140.3, 134.1, 133.6, 131.9, 130.5, 130.3, 129.4, 128.96, 128.91, 
126.9, 126.4, 125.6, 122.6, 121.6, 49.9, 44.9; IR (KBr, cm-1): 3434 (br), 2092 (br), 1792, 1644; 
MS: HR-ESI calculated for [(C20H14ClNO2)+H]+: 336.0786, found: 336.0785; HPLC 
(CHIRALPAK AS-H, hexane/isopropanol 20:1, 1 mL/min): 23.6 min (minor); 31.8 min (major); 
sign of rotation: (−). 
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Clear colorless semi-solid; 1H NMR (300 MHz, CDCl3): δ 8.12 (d, 
J= 8.5 Hz, 2H), 7.89-7.71 (m, 4H), 7.59-7.34 (m, 6H), 6.37 (m, X of 
ABX pattern, 1H), 3.61 (s, 3H), 3.11 (m, AB of ABX pattern, 2H); 
13C NMR (75 MHz, CDCl3): δ 172.2, 165.6, 138.1, 135.9, 134.2, 
132.7, 130.9, 129.2, 129.0, 128.9, 128.7, 127.1, 126.2, 125.4, 123.1, 
123.0, 52.2, 46.7, 39.1; IR (KBr, cm-1): 3298 (br), 1737, 1635, 1595, 
1539, 1486; MS: HR-ESI calculated for [(C21H18ClNO3)+Na]+: 368.1048, found: 368.1056; 
HPLC (CHIRALCEL OD-H, hexane/isopropanol 4:1, 1 mL/min): 8.9 min (major); 15.2 min 
(minor); sign of rotation: (−). 
 
Clear colorless oil; 1H NMR (300 MHz, CDCl3): δ 7.88 (d, J= 8.5 
Hz, 2H), 7.44 (d, J= 8.5 Hz, 2H), 4.20 (m, 1H), 3.00 (dd, J1= 16.5 
Hz, J2= 6.6 Hz, 1H), 2.82 (dd, J1= 16.5 Hz, J2= 2.8 Hz, 1H), 2.37 (m, 
1H), 1.00 (d, J= 6.6 Hz, 3H), 0.96 (d, J= 6.6 Hz, 3H) ; 13C NMR (75 
MHz, CDCl3): δ 165.8, 164.8, 139.8, 131.5, 130.9, 128.7, 54.9, 37.5, 
29.5, 19.0, 15.9; IR (KBr, cm-1): 3565, 2963, 2874, 1793.2, 1674, 1592, 1572, 1488, 1466, 1313; 
MS: HR-ESI calculated for [(C13H14ClNO2)+Na]+: 274.0605, found: 274.0599. HPLC: 
Converted into Me ester by treatment with MeONa/MeOH and analyzed as described below. 
 
White solid; mp: 105-108 °C; 1H NMR (300 MHz, CDCl3): δ 7.72 
(d, J= 8.5 Hz, 2H), 7.39 (d, J=  8.5 Hz, 2H), 6.94 (d (br), J= 9.1 Hz, 
1H), 4.21 (m, 1H), 3.69 (s, 3H), 2.70 (diastereotopic dd, 2H), 1.94 
(m,  1H), 0.98 (diastereotopic doublets, 6H); 13C NMR (75 MHz, 
CDCl3): δ 173.2, 165.9, 137.9, 133.3, 129.0, 128.6, 52.2, 52.1, 36.1, 
31.9, 19.7, 19.5; IR (KBr, cm-1): 3349, 2950, 2872, 1740, 1638, 1546, 1489; MS: HR-ESI 
calculated for [(C14H18ClNO3)+H]+: 284.1047, found: 284.1052; HPLC (CHIRALCEL OD-H, 
hexane/isopropanol 10:1, 1 mL/min): 6.6 min (minor); 8.4 min (major); sign of rotation:  (−). 
 
Clear, colorless oil; 1H NMR (300 MHz, CDCl3 δ 7.81 (d, J= 8.3 Hz, 
2H), 7.30 (d, J= 8.5 Hz, 2H), 4.46 (app. t, J= 5.0 Hz, 1H), 3.40 (app dd, 
J1= 8.0 Hz, J2= 4.7 Hz, 1H), 2.22 (app dd, J1= 13.8 Hz, J2= 5.2 Hz, 
1H), 1.99 (app dd, J1= 12.4 Hz, J2= 5.0 Hz, 1H), 1.83-1.72 (m, 1H), 
1.66-1.35 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 166.8, 164.8, 139.3, 
131.3, 130.9, 128.5, 56.7, 52.9, 29.2, 26.2, 23.0; IR (KBr, cm-1): 3548, 2963, 2871, 1784, 1700, 
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1592, 1489, 1402, 1317; MS: HR-ESI calculated for [(C13H12ClNO2)+Na]+: 272.0449, found: 
272.0449; HPLC (CHIRALPAK AD, hexane/isopropanol 100:1, 1 mL/min): 19.8 min (minor); 
27.2 min (major); sign of rotation: (−). 
 
White solid; mp: 95-98 °C;  1H NMR (300 MHz, CDCl3): δ 7.70 (d, 
J= 8.8 Hz, 2H), 7.40 (d, J= 7.6 Hz, 2H), 7.00 (d (br), J= 7.4 Hz, 
1H), 4.65 (app. quintet, J1= 7.4 Hz, 1H), 3.67 (s, 3H), 3.08 (app. dd, 
J1= 14.8 Hz, J2= 7.7 Hz, 1H), 2.13-1.99 (m, 3H), 1.91-1.63 (m, 3H); 
13C NMR (75 MHz, CDCl3): δ 175.8, 165.9, 137.9, 133.1, 129.0, 128.6, 52.7, 52.2, 46.3, 32.5, 
28.9, 22.6; IR (KBr, cm-1): 3339, 2944, 1722, 1641, 1541, 1488, 1325; MS: HR-ESI calculated 
for [(C14H16ClNO3)+H]+: 282.0891, found: 282.0898; HPLC (CHIRALPAK AS-H, 
hexane/isopropanol 10:1, 1 mL/min): 16.8 min (minor); 31.4 min (major); sing of rotation: (−).  
 
White solid; mp: 124-128 °C; 1H NMR (300 MHz, CDCl3): δ 7.92 
(d, J=7.7 Hz, 2H), 7.80 (d, J= 7.1 Hz, 1H), 7.33 (m, 5H), 5.63 (d, 
J= 5.5 Hz, 1H), 4.03 (m, 1H), 3.44 (app. d, J= 17.6 Hz, 1H), 3.21 
(dd, J1= 17.6 Hz, J2= 10.7 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 
167.1, 164.9, 143.9, 139.6, 138.9, 131.4, 130.5, 129.9, 128.7, 
128.4, 127.6, 126.0, 61.0, 50.7, 31.4; IR (KBr, cm-1): 3434, 1788, 1667, 1320, 1309, 1276; MS: 
HR-ESI calculated for [(C17H12ClNO2)+Na]+: 320.0447, found: 320.0449; HPLC (CHIRALCEL 
OD-H, hexane/isopropanol 100:1, 1 mL/min): 22.5 min (major); 28.2 min (minor); sign of 
rotation: (+). 
White solid; mp: 145-148 °C; 1H NMR (300 MHz, CDCl3): δ 7.72 (d, 
J= 8.8 Hz, 2H), 7.41 (d, J= 11.0 Hz, 2H), 7.35 (app d, J= 5.5 Hz, 1H), 
7.29-7.20 (m, 3H), 6.95 (d (br), J= 9.1 Hz, 1H), 6.01 (app t, J= 8.53 Hz, 
1H), 3.74-3.67 (m, 1H), 3.65 (s, 3H), 3.41 (dd, J1= 16.2 Hz, J2= 5.8 Hz, 
1H), 3.23 (dd, J1= 16.2 Hz, J2= 8.5 Hz, 1H); 13C NMR (75 MHz, 
CDCl3): δ 174.3, 166.1, 141.4, 141.1, 138.1, 132.8, 129.1, 128.9, 128.7, 127.7, 125.0, 124.7, 
55.7, 52.3, 47.9, 34.8; IR (KBr, cm-1): 3435, 2100, 1726, 1643, 1528; MS: HR-ESI calculated 
for [(C18H16ClNO3)+H]+: 330.0891, found: 330.0893; HPLC (CHIRALCEL OD-H, 
hexane/isopropanol 100:1, 1 mL/min): 71.8 min (minor); 81.0 min (major); sign of rotation: (+). 
 
Clear, colorless oil; 1H NMR (300 MHz, CDCl3): δ 7.90 (d, J= 8.5 Hz, 
2H), 7.41 (d, J= 8.8 Hz, 2H), 4.39 (m, 1H), 3.33 (m, 1H), 2.16-2.08 (m, 
1H), 1.97-1.75 (m, 3H), 1.68-1.50 (m, 4H); 13C NMR (75 MHz, 
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CDCl3): δ 172.6, 169.9, 143.9, 135.7, 135.3, 133.0, 53.8, 50.2, 27.9, 24.4, 23.8, 21.7; IR (KBr, 
cm-1): 3547, 2943, 2867, 1785, 1668, 1591, 1325, 1296, 1284; MS: HR-ESI calculated for 
[(C14H14ClNO2)+Na]+: 286.0605, found: 286.0600; HPLC (CHIRALPAK AS-H, 
hexane/isopropanol 100:1, 0.8 mL/min): 17.2 min (minor); 20.4 min (major); sign of rotation: 
(−). 
White solid; mp: 116-118 °C; 1H NMR (300 MHz, CDCl3): δ 7.70 
(d, J= 8.5 Hz, 2H), 7.41 (d, J= 8.5 Hz, 2H), 7.30 (d (br), J= 8.8 Hz, 
1H), 4.34-4.25 (m, 1H), 3.72 (s, 3H), 2.91 (app. q, J= 4.3 Hz, 1H), 
2.21-2.15 (m, 1H), 1.82-1.44 (m, 6H), 1.31-1.22 (m, 1H); 13C NMR 
(75 MHz, CDCl3): δ 175.2, 165.4, 137.8, 133.3, 128.9, 128.6, 52.0, 48.7, 44.5, 29.6, 27.7, 24.6, 
22.6; IR (KBr, cm-1): 3319, 2936, 2859, 1731, 1639, 1527, 1484; MS: HR-ESI calculated for 
[(C15H18ClNO3)+H]+: 296.1081, found: 296.1051; HPLC (CHIRALPAK AS-H, 
hexane/isopropanol 20:1, 1 mL/min): 25.1 min (minor); 32.1 min (major); sign of rotation: (−). 
 
Clear, colorless crystals; mp: 61-66 °C; 1H NMR (300 MHz, CDCl3): δ 
7.84 (d, J= 8.5 Hz, 2H), 7.38 (d, J= 8.5 Hz, 2H), 5.93-5.88 (m, 1H), 
5.82-5.76 (m, 1H), 4.54 (app. t, J= 5.2 Hz, 1H), 3.45 (app t, J= 7.0 Hz, 
1H), 2.87 (app. dd, J1= 17.9 Hz, J2= 6.6 Hz, 1H), 2.57-2.49 (app dd, 
1H), 2.24-2.17 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 166.9, 165.3, 
139.6, 131.4, 130.9, 128.6, 126.2, 125.6, 49.7, 46.2, 24.6, 21.6; IR (KBr, cm-1): 3567, 3040, 
2842, 1787, 1670, 1319; MS: HR-ESI calculated for [(C14H12ClNO2)+Na]+: 284.0435, found: 
284.0441; HPLC (CHIRALPAK AS-H, hexane/isopropanol 50:1, 1 mL/min): 12.1 min (minor); 
15.1 min (major); sign of rotation: (−).  
 
White solid; mp: 126-128 °C; 1H NMR (300 MHz, CDCl3): δ 7.70 
(d, J= 8.5 Hz, 2H), 7.40 (d, J= 8.5 Hz, 2H), 7.04 (d (br), J= 9.1 Hz, 
1H), 5.68 (m, 2H), 4.65 (m, 1H), 3.72 (s, 3H), 2.94 (m, J1= 9.6 Hz, 
J2= 5.8 Hz, 1H), 2.68-2.59 (m, 1H), 2.48-2.38 (m, 2H), 2.33-2.23 
(m, 1H); 13C NMR (75 MHz, CDCl3): δ 174.6, 165.9, 137.9, 133.2, 129.0, 128.6, 125.2, 125.1, 
52.3, 45.7, 42.1, 30.0, 26.4; IR (KBr, cm-1): 3332, 3028, 2948, 1732, 1635, 1534, 1486; MS: 
HR-ESI calculated for [(C15H16ClNO3)+H]+: 294.0891, found: 294.0897; HPLC (CHIRALPAK 
AS-H, hexane/isopropanol 5:1, 1 mL/min): 12.7 min (minor); 21.8 min (major); sign of rotation: 
(+). 
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White solid; mp:106-108 °C; 1H NMR (300 MHz, CDCl3): δ 7.90 (d, 
J=8.8 Hz, 2H), 7.42 (d, J= 8.8 Hz, 2H), 4.01 (app. d, J=4.7 Hz, 1H), 
3.06 (app. d, J= 4.7 Hz, 1H), 2.89 (app. d, J= 3.3 Hz, 1H), 2.57 (app. d, 
J= 2.5 Hz, 1H), 1.74-1.58 (m, 3H), 1.35 (app d, J= 11.3 Hz, 1H), 1.2 
(m, 2H); 13C NMR (75 MHz, CDCl3): δ 165.5, 164.9, 139.5, 131.3, 
130.8, 128.6, 55.92, 55.89, 55.4, 37.6, 35.3, 31.6, 27.4, 24.8; IR (KBr, cm-1): 3546, 2963, 2874, 
1782, 1669, 1593, 1401, 1323; MS: HR-ESI calculated for [(C15H14ClNO2)+Na]+: 298.0605, 
found: 298.0605; HPLC (CHIRALPAK AD, hexane/isopropanol 100:1, 1 mL/min): 23.7 min 
(minor); 37.5 min (major); sign of rotation: (+). 
 
White solid; mp: 101-105 °C; 1H NMR (300 MHz, CDCl3): δ 7.58 
(d, J= 8.5 Hz, 2H), 7.42 (d (br), J= 8.5 Hz, 1H), 7.25 (d, J= 8.5 Hz, 
2H), 4.26 (app. t, J= 8.5 Hz, 1H), 3.51 (s, 3H), 2.69 (app d, J= 8.5 
Hz, 1H), 2.36 (app s, 1H), 2.16 (app d, J= 3.0 Hz, 1H), 1.84 (app d, 
J= 10.7 Hz, 1H), 1.47 (m, 2H), 1.30-1.17 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 174.9, 165.3, 
137.6, 133.1, 128.9, 128.5, 54.7, 51.9, 51.3, 42.8, 41.6, 34.9, 29.0, 26.5; IR (KBr, cm-1): 3314, 
2958, 2874, 1730, 1646, 1595, 1532, 1484; MS: HR-ESI calculated for [(C16H18ClNO3)+H]+: 
308.1048, found: 308.1052; HPLC (CHIRALPAK AD, hexane/isopropanol 20:1, 0.8 mL/min): 
26.21 min (major); 45.7 min (minor); sign of rotation: (+). 
 
White solid; mp: 106-109 °C; 1H NMR (300 MHz, CDCl3): δ 7.93 (d, 
J= 8.5 Hz, 2H), 7.43 (d, J= 8.5 Hz, 2H), 6.32 (m, 1H), 6.23 (m, 1H), 
4.07 (app. d, J= 4.7 Hz, 2H), 3.45 (app s, 1H), 3.10 (m, 2H), 1.76-1.61 
(m, 2H); 13CNMR (75MHz, CDCl3): δ 165.6, 165.2, 139.7, 138.6, 
136.6, 131.4, 130.6, 128.7, 55.6, 54.9, 43.5, 41.2, 40.5; IR (KBr, cm-1): 
2985, 2360, 1787, 1669, 1592, 1489, 1401, 1320, 1282; MS: HR-ESI calculated for 
[(C15H12ClNO2)+Na]+: 296.0449, found: 296.0447; HPLC (CHIRALPAK AD, 
hexane/isopropanol 100:1, 1 mL/min): 19.0 min (major); 23.3 min (minor); sign of rotation: (+). 
 
White solid; mp: 128-131 °C; 1H NMR (300 MHz, CDCl3): δ 7.72 
(d, J= 8.5 Hz, 2H), 7.64 (d (br), J= 8.8 Hz, 1H), 7.41 (d, J= 8.3 Hz, 
2H), 6.30 (m, 1H), 6.25 (m, 1H), 4.31 (app. t, J= 8.5 Hz, 1H), 3.69 
(s, 3H), 3.03 (app s, 1H), 2.87 (app s, 1H), 2.71 (app. d, J= 8.3 Hz, 
1H), 2.02 (app d, J= 9.7 Hz), 1.61 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 175.9, 165.6, 138.3, 
137.9, 137.7, 133.0, 129.1, 128.5, 53.4, 51.5, 48.9, 47.2, 45.5, 44.4; IR (KBr, cm-1): 3434 (br), 
2092 (br), 1644, 1533, 1484; MS: HR-ESI calculated for [(C16H16ClNO3)+H]+: 306.0891, found: 
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306.0890; HPLC (CHIRALPAK AS-H, hexane/isopropanol 4:1, 0.8 mL/min): 9.6 min (minor); 
19.3 min (major); sign of rotation: (−). 
 
Clear, faint yellow oil; 1H NMR (300 MHz, CDCl3): δ 8.01 (d, J= 
8.3 Hz, 2H), 7.47-7.30 (m, 7H), 4.94 (d, J= 3.6 Hz, 1H), 3.23 (m, 
1H), 1.99-1.77 (m, 2H), 1.54-1.28 (m, 4H), 0.94 (t, J= 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 167.8, 165.1, 140.0, 138.4, 
131.7, 130.6, 129.2, 128.8, 128.6, 126.1, 59.2, 58.1, 29.3, 28.6, 
22.7, 14.0; IR (KBr, cm-1): 3553 (broad), 3089, 3065, 3032, 2957, 2930, 2859, 1790, 1670, 
1592, 1573, 1489, 1458, 1401, 1298 (broad); MS: HR-ESI calculated for [(C20H20ClNO2)+H]+: 
342.1255, found: 342.1252.  
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5.3 KR OF Β-LACTAMS VIA ENANTIOSELECTIVE N-ACYLATION USING AMIDINE-BASED 
CATALYSTS 
 
5.3.1 General 
See Chapter III for substrate notation/numbering. Racemic β-lactams III-1, III-3, III-10, and 
III-12 were obtained via cycloaddition of chlorosulfonyl isocyanate with the corresponding 
olefins.1 Substrate III-9 was prepared via alkylation of (±)-III-1 as previously described.2 All 
other substrates were synthesized from the corresponding aldehydes via condensation of their N-
(trimethylsilyl)imines with tert-butyl acetate Li enolate, according to a general procedure.3 
5.3.2  Kinetic resolution experiments 
General Procedure: A racemic β-lactam (0.10 mmol) and (S)-Cl-PIQ (2.8 mg, 0.010 mmol) 
were stirred in 2 mL of tert-amyl alcohol at rt for ca. 10 min until most of the solids dissolved. 
Then, i-Pr2NEt (34 μL, 0.20 mmol) was added, the solution was cooled to 0 oC and stirred for 5 
min, and treated with isobutyric anhydride (34 μL, 0.20 mmol). After stirring at 0 oC for 24-72 h, 
the reaction mixture was quenched by addition of methanol (100 μL) and the solvent removed 
under vacuum. After determining the % conversion in the crude residue by 1H NMR, it was 
separated by flash chromatography (hexanes/EtOAc 1:1 in all cases, except substrates III-9 and 
III-10 requiring 2:1 ratio). The enantiomeric enrichment of the N-acylated product and the 
recoved β-lactam were analyzed by HPLC. The calculated value for conversion was in 
agreement with that estimated by 1H NMR. The results are provided from duplicate runs, unless 
otherwise specified and are summarized in Table 5.3.2-2.  
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Optimization Study Procedure: Optimization studies were conducted in a similar fashion using 
General Procedure, except 0.025 mmol (3.6 mg) of 4-phenyl-azetidin-2-one III-1. The 
conditions and results of these experiments are summarized in Table 5.3.2-1. Reaction mixtures 
were analyzed HPLC, by removing aliquots, diluting them with CH2Cl2 and hexane, and 
injecting directly into the HPLC line.  
Preparative Scale Resolution Procedure: Racemic 4-(p-chlorophenyl)-azetidin-2-one III-3 
(545 mg, 3.00 mmol), (R)-Cl-PIQ (84 mg, 0.30 mmol), and N,N′-diisopropylethylamine (1.0 mL, 
6.0 mmol) were dissolved in 60 mL of tert-amyl alcohol.  After cooling the reaction mixture to 0 
°C, isobutyric anhydride (1.0 mL, 6.0 mmol) was added and the stirring continued for 30 h at the 
same temperature, whereupon the reaction was quenched with 3 mL of methanol. After rotary 
evaporation of the solvent, the crude mixture was applied directly to a silica gel column and 
eluted first with dichloromethane, then 1:1 hexane/ethyl acetate mixture and finally isopropanol 
with 5% triethylamine until the bright-yellow catalyst was eluted (55 mg, 65% recovery). The 
(R)-enantiomer of the N-acylated product was isolated with 74.4% ee (438 mg, ca. 98% pure, 
57% yield); the (S)-enantiomer of the starting material was recovered with 97.9% ee (234 mg, 
ca. 98% pure, 42% yield). According to Kagan’s equation, the reaction proceeded to 56.8% 
conversion with 29.8 selectivity factor (cf. Table 5.3.2-2, entry 2). 
Table 5.3.2-1: KR of β-lactams: Optimization study 
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Entryg catalyst solvent temp, °C time, h eePR % eeSM % 
CHPLC 
% 
s 
1 (R)-BTM CDCl3 23 24 ND ND 0a ND 
2 (S)-HBTM CDCl3 23 48 ND ND ~10a ND 
3 (R)-Cl-PIQ CDCl3 23 24 75.2 36.4 33 10 
4b (R)-Cl-PIQ CDCl3 23 4.0 1.88 0 35a 1.0 
5c (R)-Cl-PIQ CDCl3 23 10 22.6 12.2 35 1.8 
6 (R)-Cl-PIQ CD2Cl2 23 24 64.7 17.4 21 5.5 
7 (R)-Cl-PIQ THF 23 24 68.9 19.7 22 6.6 
8d (R)-Cl-PIQ EtMe2COH 23 10 78.4 65.3 45 16 
9d (R)-Cl-PIQ EtMe2COH 0 24 80.8 73.1 47 20 
10e (R)-Cl-PIQ EtMe2COH 0 48 85.6 42.7 33 19 
11f (R)-Cl-PIQ EtMe2COH 0 24 86.2 46.3 35 21 
12d (R)-Cl-PIQ HC≡CMe2COH 23 10 80.3 55.9 41 16 
See Optimization Study Procedure: 0.1 M (±)-III-1, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.01 M 
(10 mol%) catalyst, unless specified otherwise. a) Conversion was determined by 1H NMR. b) 
(MeCO)2O was used instead of (i-PrCO)2O. c) (EtCO)2O was used instead of (i-PrCO)2O. d) 0.05 
M (±)-III-1 and 0.005 M (10 mol%) (R)-Cl-PIQ was used. e) 0.05 M (±)-III-1 and 0.0025 M (5 
mol%) (R)-Cl-PIQ were used. f) 0.05 M (±)-III-1, 0.05 M (i-PrCO)2O, 0.05 M i-Pr2NEt, and 
0.005 M (10 mol%) (R)-Cl-PIQ, were used. g) Results based on single runs. 
 
Table 5.3.2-2: KR of β-lactams: Substrate scope 
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entry substrate time # 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1 
III-1 
24 
1 84.1 62.0 42.4 21.8 
43 22 
2 83.5 63.4 43.1 21.3 
2  
III-3 
30 
1 78.5 94.6 54.6 29.7 
54 30 
2 80.4 93.2 53.6 31.2 
3 
III-4 
30 
1 89.8 69.0 43.4 38.5 
42 38 
2 90.1 63.1 41.2 36.8 
4 
 
III-5 
30 
1 46.0 8.62 15.8 2.94 
14 3.1 
2 50.0 7.28 12.7 3.22 
5b 
 
III-6 
72 
1 83.1 54.2 39.6 18.5 
41 19 
2 82.8 59.9 42.0 19.4 
6 
III-7 
30 
1 85.9 97.3 53.1 56.0 
53 54 
2 84.7 97.5 53.5 52.3 
7   
III-8 
30 
1 65.3 94.7 59.2 16.7 
59 17 
2 65.0 94.9 59.4 16.6 
 
8b 
 
 
III-9 
 
72 
 
1 
 
81.2 
 
47.2 
 
36.8 
 
15.3  
38 
 
16 
2 82.2 51.7 38.6 17.0 
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9b,d 
III-10 
72 1 79.6 25.6 24.3 11.3 26 13 
2 82.4 31.2 27.5 14.1 
10 
  
III-11 
30 
1 78.8 54.4 40.9 14.4 
42 14 
2 77.5 57.9 42.8 14.1 
11c 
III-12 
24 
1 ND ND 0e ND 
0e ND 
2 ND ND 0
e ND 
See General Procedure: 0.05 M racemic substrate, 0.1 M (i-PrCO)2O, 0.1 M i-Pr2NEt, 0.01 M 
(10 mol%) (R)-Cl-PIQ, tert-amyl alcohol, 0 °C, unless specified otherwise. The data reported are 
averages of duplicate runs. a) Absolute configuration of the fast reacting enantiomer is shown.b) 
0.2 M (4 equiv) of (i-PrCO)2O and i-Pr2NEt were used. c) reaction performed in CDCl3 at rt. d) 
Absolute stereochemistry notation is inverted in this case according to CIP nomenclature rules. e) 
determined by 1H NMR. 
 
5.3.3  Characterization data and HPLC properties 
Note: Absolute configuration was established on the basis of prior literature reports in the case 
of substrates III-1 and III-11. In all other cases, it was assigned by analogy. 
 
Previously reported.4  1H NMR (400 MHz, CDCl3) δ 2.85 (dd, J1= 15.0 Hz, J2= 
0.9 Hz, 1H), 3.42 (ddd, J1= 15.0 Hz,  J2= 5.1 Hz, J3= 1.8 Hz, 1H), 4.71 (dd, J1 = 
5.1 Hz, J2= 2.3 Hz, 1H), 6.59 (bs, 1H), 7.10-7.60 (m, 5H); HPLC (CHIRALCEL 
AD-H, isopropanol/hexane 1:50, 0.8 mL/min): 35.8 min (minor), 39.4 min 
(major). 
 
Previously reported.5 HPLC (CHIRALCEL AD-H, isopropanol/hexane 1:50, 
1 mL/min): 18.3 min; 26.4 min. 
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White solid. mp. 82-83 °C. 1H NMR (300 MHz, CDCl3):  δ 7.41-7.29(m, 
5H), 5.02 (dd, J1 = 6.6 Hz, J2 = 3.3 Hz, 1H), 3.49 (dd, J1 = 16.2 Hz, J2 = 6.3 
Hz, 1H), 2.96 (dd, J1 = 16.5 Hz, J2 = 3.3 Hz, 1H), 2.82-2.74 (m, 2H), 1.16 
(t, J = 7.2Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 171.8, 165.4, 138.1, 
129.2, 128.7, 126.1, 52.4, 45.6, 30.4, 8.1; IR (KBr, cm-1) 3032, 2980, 1787, 
1704, 1374, 1282, 698; MS: HR-ESI calculated for [C12H13NO2+H]+: 204.1019, found: 
204.1028. HPLC (CHIRALCEL AD-H, isopropanol/hexane 1:50, 1 mL/min): 15.6 min (minor), 
20.3 min (major). 
 
White solid; mp: 95-97 °C; 1H NMR (300 MHz, CDCl3): δ 7.39-7.28 (m, 
5H), 5.02 (dd, J1 = 9.9 Hz, J2 = 3.3 Hz, 1H), 3.53 (dd, J1=16.5, J2= 6.6 Hz, 
1H), 3.41 (septet, J = 6.9 Hz, 1H), 2.97 (dd, J1= 16.2 Hz, J2= 3.3 Hz, 1H), 
1.25 (d, J=7.1 Hz, 3H), 1.17 (d, J=7.1Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ 175.1, 165.1, 138.3, 129.2, 128.6, 125.9, 52.2, 45.5, 35.1, 19.1, 
17.8; IR (KBr, cm-1): 2973, 1775, 1697, 1285, 1253; MS: HR-ESI calculated for 
[(C13H15NO2)+H]+: 218.1176, found: 218.1175. HPLC (CHIRALCEL AD-H, 
isopropanol/hexane 1:50, 0.8 mL/min): 11.3 min (minor), 13.4 min (major). 
 
Previously reported.6 1H NMR (400 MHz, CDCl3): δ 7.26-7.36 (m, 4H), 6.30 
(s, br, 1H), 4.70-4.72 (dd, J1= 2.4 Hz; J2= 5.2 Hz, 1H), 3.45 (1H, ddd,  J1= 14.9 
Hz, J2= 5.3 Hz, J3 = 2.6 Hz, 1H), 2.84 (dd, J1= 14.9 Hz, J2 = 1.8 Hz, 1H); 
HPLC: Converted into its corresponding N-isobutyryl derivative and analyzed 
as described below.  
 
White solid; mp: 80-81 °C. 1H NMR (300 MHz, CDCl3): δ 7.34 (d, J = 
8.7 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 4.98 (dd, J1 = 6.6 Hz, J2 = 3.3 Hz, 
1H), 3.49 (dd, J1 = 16.5 Hz, J2 = 6.3 Hz, 1H), 3.30-3.21 (m, 1H), 2.91 (dd, 
J1 = 16.5 Hz, J2 = 3.3 Hz, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.6 
Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.2, 164.7, 136.8, 134.5, 
129.4, 127.4, 51.6, 45.4, 35.2, 19.1, 17.7; IR (KBr, cm-1) 2975, 1788, 1703, 1277, 1089; MS: 
HR-ESI calculated for [C13H14ClNO2+H]+ : 252.0786, found: 252.0788; HPLC (CHIRALCEL 
AD-H, isopropanol/hexane 1:50, 1.0 mL/min): 11.5min (minor), 20.9 min (major). 
 
Previously reported.7 1H NMR (200 MHz CDCl3): δ 7.28 (m, 2H), 6.89 (m, 
2H), 6.29 (bs, 1H), 4.67 (dd, J1= 5.3 Hz,  J2= 2.6 Hz, 1H), 3.40 (ddd, J1= 
14.9 Hz, J2= 5.3 Hz, J3= 2.4 Hz, 1H), 2.83 (ddd, J1= 14.9 Hz, J2= 2.6 Hz, 
97 
 
J3= 0.8 Hz, 1H); HPLC: Converted into its corresponding N-isobutyryl derivative and analyzed 
as described below. 
 
 
Colorless oil.1H NMR (300 MHz, CDCl3): δ 7.24 (d, J = 9.0 Hz, 2H), 
6.89 (m, J = 8.7 Hz 2H), 4.96 (dd, J1 = 6.6 Hz, J2 = 3.3 Hz, 1H), 3.80 (s, 
3H), 3.45 (dd, J1 = 16.5 Hz, J2 = 6.3 Hz, 1H), 3.30-3.20 (m, 1H), 2.93 
(dd, J1 = 16.5 Hz, J2 = 3.3 Hz, 1H), 1.20 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 
6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.2, 165.3, 159.9, 130.2, 
127.3, 114.6, 55.5, 51.9, 45.4, 35.1, 19.1, 17.8; IR (KBr, cm-1) 2972, 
1783, 1700, 1515, 1279, 1248; MS: HR-ESI calculated for [C14H17NO3+H]: 248.1281, found: 
248.1285; HPLC (CHIRALCEL AD-H, isopropanol/hexane 1:50, 1.0 mL/min): 18.7min 
(minor), 23.0 min (major). 
 
Previously reported.6 1H NMR (400 MHz, CDCl3): δ 7.26-7.47 (m, 4H), 6.33 (s, 
br, 1H), 5.06 (dd, J1= 5.4 Hz, J2= 2.6 Hz, 1H), 3.52-3.58 (ddd, J1= 8.3 Hz, J2= 
5.4 Hz, J3= 2.9 Hz, 1H), 2.83 (dd, J1= 14.9 Hz, J2 = 2.6 Hz, 1H); HPLC 
(CHIRALCEL AD-H, isopropanol/hexane 1/20, 1 mL/min): 15.7 min (minor), 
20.5 min (major).  
 
Yellowish oil. 1H NMR (300 MHz, CDCl3): δ 7.40-7.36 (m, 1H), 7.28-7.23 
(m, 2H), 7.15-7.10 (m, 1H), 5.35 (dd, J1 = 6.3 Hz, J2 = 3.6 Hz, 1H), 3.60 
(dd, J1 = 16.2 Hz, J2 = 6.3 Hz, 1H), 3.39-3.29 (m, 1H), 2.85 (dd, J1 = 16.5 
Hz, J2 = 3.3 Hz, 1H), 1.32 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 6.6 Hz, 3H); 13C 
NMR (75 MHz, CDCl3): δ 175.4, 164.7, 135.6, 132.6, 130.1, 129.4, 127.4, 
125.9, 50.2, 44.9, 35.2, 19.4, 17.7; IR (KBr, cm-1) 2974, 1790, 1704, 1273, 755; MS: HR-ESI 
calculated for [C13H14ClNO2+H]+: 252.0786, found: 252.0789; HPLC (CHIRALCEL AD-H, 
IPA:Hexane 1:50, 1 mL/min): 10.7 min (major), 12.7 min (minor). 
 
Previously reported without characterization.8 White solid, mp: 153-155 °C. 
1H NMR (300 MHz, DMSO): δ 8.62 (br, 1H), 7.95-7.84 (m, 3H), 7.59-7.49 
(m, 4H), 5.29 (dd, J1 = 4.8 Hz, J2 = 2.4 Hz, 1H), 3.63 (ddd, J1 = 14.4 Hz, J2 = 
4.8 Hz, J3 = 2.4 Hz, 1H), 2.58 (dd, J1 = 14.4 Hz, J2 = 2.4 Hz, 1H); 13C NMR 
(75 MHz, DMSO): δ 167.6, 137.9, 133.8, 130.4, 129.3, 128.3, 127.1, 126.7, 
126.1, 123.7, 122.3, 47.5, 47.2; IR (KBr, cm-1) 3246, 1753, 800, 777; MS: HR-ESI calculated 
for [C13H11NO+H]: 198.0913, found: 198.0913; HPLC (CHIRALCEL OD-H, 
isopropanol/hexane 1:4, 1.0 mL/min): 14.6 min (minor), 26.0 min (major). 
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White solid, mp: 110-112 °C. 1H NMR (300 MHz, CDCl3): δ 7.92-7.80 
(m, 3H), 7.58-7.43 (m, 3H), 7.25 (d, J = 6.9 Hz, 1H), 5.75 (dd, J1 = 6.6 
Hz, J2 = 3.6 Hz, 1H), 3.73 (dd, J1 = 16.2 Hz, J2 = 6.6 Hz, 1H), 3.47-3.39 
(m, 1H), 2.89 (dd, J1 = 16.2 Hz, J2 = 3.6 Hz, 1H), 1.41 (d, J = 6.9 Hz, 
3H) 1.24 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.6, 
165.0, 134.0, 133.5, 130.2, 129.4, 128.7, 126.8, 126.2, 125.6, 122.5, 121.5, 50.1, 45.7, 35.4, 19.6, 
17.7; IR (KBr, cm-1) 3052, 2973, 1785, 1701, 1275, 776; MS: HR-ESI calculated for 
[C17H17NO2+H]: 268.1332, found: 268.1338; HPLC (CHIRALCEL AD-H, isopropanol/hexane 
1:20, 1.0 mL/min): 12.4 min (major), 16.4 min (minor). 
 
White crystals; mp: 154-155 °C. 1H NMR (300 MHz, DMSO): δ 8.50 (br, 
1H), 7.94-7.87 (m, 4H), 7.54-7.47 (m, 3H), 4.80 (dd, J1 = 5.4 Hz, J2 = 2.4 
Hz, 1H), 3.42 (ddd, J1 = 14.7 Hz, J2 = 5.4 Hz, J3 = 2.4 Hz, 1H), 2.58 (dd, J1 
= 14.7 Hz, J2 = 1.8 Hz, 1H); 13C NMR (75 MHz, DMSO): δ 167.8, 139.8, 
133.5, 133.2, 129.0, 128.4, 128.3, 127.1, 126.7, 125.0, 124.5, 49.5, 47.8; 
IR (KBr, cm-1) 3247, 3053, 2955, 1742, 1357, 1181, 821; MS: HR-ESI calculated for 
[C13H11NO+H]: 198.0913, found: 198.0924; HPLC: Converted into its corresponding N-
isobutyryl derivative and analyzed as described below. 
 
White solid; mp: 112-113 °C. 1H NMR (300 MHz, CDCl3): δ 7.88-
7.78 (m, 4H), 7.52-7.46 (m, 2H), 7.39 (dd, J1 = 8.7 Hz, J2 = 2.1 Hz, 
1H), 5.18 (dd, J1 = 6.3 Hz, J2 = 3.3 Hz, 1H), 3.55 (dd, J1 = 16.5 Hz, J2 
= 6.3 Hz, 1H), 3.61-3.27 (m, 1H), 3.04 (dd, J1 = 16.5 Hz, J2 = 3.3 Hz, 
1H), 1.26 (d, J = 6.9 Hz, 3H) 1.18 (d, J = 6.6 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 175.2, 165.1, 135.5, 133.5, 133.5, 129.3, 128.2, 128.0, 126.8, 126.6, 125.7, 
122.9, 52.4, 45.5, 35.2, 19.1, 17.8; IR (KBr, cm-1) 3054, 2973, 1786, 1702, 1386, 1280, 747; 
MS: HR-ESI calculated for [C17H17NO2+H]: 268.1332, found: 268.1334; HPLC (CHIRALCEL 
AD-H, isopropanol/hexane 1:20, 1.0 mL/min): 9.4 min (minor), 14.3 min (major). 
 
Yellow solid; mp: 72-74 °C. 1H NMR (300 MHz, DMSO): δ 8.50 (br, 1H), 
7.47 (dd, J1 = 5.4 Hz, J2 = 1.2 Hz, 1H), 7.09 (d, J = 3.3 Hz, 1H), 6.99 (dd, J1 = 
4.8 Hz, J2 = 3.6 Hz, 1H), 4.90 (dd, J1 = 5.4 Hz, J2 = 2.4 Hz, 1H), 3.36 (ddd, J1 = 
14.7 Hz, J2 = 5.1 Hz, J3 = 2.1 Hz, 1H), 2.76 (dd, J1 = 14.7 Hz, J2 = 1.8 Hz, 1H); 
13C NMR (75 MHz, DMSO): δ 167.6, 146.6, 127.8, 125.9, 125.6, 46.7, 45.5; 
99 
 
MS: HR-ESI calculated for [C7H7NOS+H]+: 154.0321, found: 154.0322; HPLC (CHIRALCEL 
OD-H, isopropanol/hexane 1:10, 1.0 mL/min): 15.3 min (minor); 16.8 min (major). 
 
Colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.27 (dd, J1 = 5.4 Hz, J2 = 
1.5 Hz, 1H), 7.11 (m, 1H), 6.98 (dd, J1 = 5.4 Hz, J2 = 3.6 Hz, 1H), 5.29 
(dd, J1 = 6.6 Hz, J2 = 3.3 Hz, 1H), 3.53 (dd, J1 = 16.5 Hz, J2 = 6.3 Hz, 1H), 
3.26-3.17(m, 1H), 3.13 (dd, J1 = 16.5 Hz, J2 = 3.3 Hz, 1H), 1.20 (d, J = 6.9 
Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.1, 
164.5, 141.4, 127.3, 126.5, 125.7, 48.2, 45.8, 35.2, 19.1, 17.7; IR (KBr, cm-1) 2974, 1788, 1702, 
1276, 704; MS: HR-ESI calculated for [C11H13NO2S+H]+: 224.074, found: 224.0745; HPLC 
(CHIRALCEL AD-H, isopropanol/hexane 1:100, 1.0 mL/min): 15.1 min (minor), 18.2 min 
(major). 
 
Previously reported.2 1H NMR (300 MHz, CDCl3): δ 7.30 (s, 5H), 7.0 (s, br, 
1H), 4.25 (d, J = 2.0 Hz, 1H), 2.95 (dt, J1= 7.0 Hz, J2 = 2.0 Hz, lH), 0.8-2.1 (m, 
9H); HPLC (CHIRALCEL AD-H, IPA:Hexane 1:50, 1.0 mL/min): 20.2 min 
(minor); 23.3 min (major).  
 
 
Colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.39-7.24 (m, 5H), 4.65 (d, J 
= 3.3 Hz, 1H), 3.33-3.24 (m, 1H), 3.09-3.03 (m, 1H), 1.96-1.73 (m, 2H), 
1.50-1.27 (m, 4H) 1.24 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 0.93 (t, 
J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 175.2, 168.3, 138.1, 128.9, 
128.2, 125.5, 59.0, 58.9, 35.0, 29.1, 28.4, 22.4, 18.9, 17.5, 13.8; IR (KBr, 
cm-1) 2931, 1784, 1704, 1273, 696; MS: HR-ESI calculated for [C17H23NO2+H]+: 274.1802, 
found: 274.1805; HPLC (CHIRALCEL AD-H, isopropanol/hexane 1:50, 1.0 mL/min): 6.1 min 
(minor), 7.1 min (major). 
 
Previously reported.9 1H NMR (270 MHz, CDCl3): δ 7.84 (m, 3H), 7.72 (s, 
1H),  7.47-7.53 (m, 2H), 7.31-7.34 (m, 1H), 6.36 (br s,1H), 4.66 (s, 1H),  
1.53 (s, 3H), 0.79 (s, 3H); HPLC (CHIRALCEL AD-H, isopropanol/  
hexane 1:50, 1 mL/min): 35.0 min (major), 39.8 min (minor) 
(stereochemical notation inverted according to CIP nomenclature rules). 
 
White solid; mp: 101-102 °C. 1H NMR (300 MHz, CDCl3): δ 7.86-
7.78 (m, 3H), 7.55 (s, 1H), 7.52-7.44 (m, 2H), 7.20 (dd, J1 = 5.4 Hz, J2 
= 1.5 Hz, 1H), 4.96 (s, 1H), 3.45-3.36 (m, 1H), 1.55 (s, 3H), 1.39 (d, J 
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= 6.9 Hz, 3H), 1.21 (d, J = 6.9 Hz, 3H), 0.84 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 175.9, 
171.9, 133.4, 133.3, 133.0, 128.7, 128.1, 128.0, 126.7, 126.4, 125.1, 123.8, 64.8, 55.1, 35.5, 23.4, 
19.6, 18.2, 17.8; IR (KBr, cm-1) 2971, 1785, 1705, 1386, 1280; MS: HR-ESI calculated for 
[C19H21NO2+H]: 296.1645, found: 296.1647; HPLC (CHIRALCEL AD-H, isopropanol/hexane 
1:50, 1 mL/min): 12.5 min (minor), 18.7 min (major) (stereochemical notation inverted 
according to CIP nomenclature rules). 
 
Previously reported.10 1H NMR (400 MHz, CDCl3): δ )7.21–7.34 (m, 4H), 
6.23 (br s, 1H), 5.03 (d, J= 4.2 Hz, 1H), 4.03 (d, J= 10.5 Hz, 1H), 3.35 (d, J= 
17.3 Hz, 1H), 3.07 (dd, J1= 17.5 Hz, J2= 10.5 Hz, 1H); HPLC (CHIRALCEL 
OD-H, IPA:Hexane 1:20, 1.0 mL/min): 19.0 min (minor), 29.1min (major). 
 
Colorless oil. 1H NMR (300 MHz, CDCl3): δ 7.68 (d, J = 7.2 Hz, 1H), 
7.35-7.22 (m, 3H), 5.43 (d, J = 5.1 Hz, 1H), 4.04-3.97 (m, 1H), 3.41-3.03 
(m, 3H), 1.17 (d, J = 6.9 Hz, 3H) 1.03 (d, J = 6.6 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 175.2, 168.0, 143.7, 138.7, 129.7, 128.2, 127.5, 125.9, 
60.7, 51.5, 34.9, 31.0, 18.7, 18.1; IR (KBr, cm-1) 2974, 1784, 1698, 1293, 
761; MS: HR-ESI calculated for [C14H15NO2+H]+: 230.1176, found: 230.1179; HPLC 
(CHIRALCEL AD-H, isopropanol/hexane 1:100, 1.0 mL/min): 8.1 min (major); 10.0 min 
(minor). 
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2 Durst, T.; Van Den Elzen, R.; Legault, R. Can. J. Chem. 1974, 52, 3206. 
3 a) Cainelli, G.; Giacomini, D.; Panunzio, M.; Martelli, G.; Spunta, G. Tetrahedron Lett. 1987, 
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Lett. 1996, 37, 2467.  
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5.4 KR OF N-ACYL-THIOLACTAMS VIA ENANTIOSELECTIVE DE-ACYLATION USING 
AMIDINE-BASED CATALYSTS 
 
5.4.1  General 
See Chapter IV for substrate notation/numbering. Racemic thazolidine-2-thiones and 
oxazolidine-2-thiones were prepared according to previously described procedures. 1,2 Their N-
acylated derivatives were prepared via DMAP-catalyzed acylation with anhydrides as previously 
reported.3 
5.4.2  Kinetic Resolution experiments 
5.4.2.1 Optimization studies 
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General procedure. To a solution of a racemic substrate (0.05 mmol) in 0.2 mL of CDCl3 was added 0.2 
mL of a stock solution of 0.025 M (R)-BTM (0.005 mmol) and 0.025 M benzoic acid (0.005 mmol) in 
CDCl3 followed by 0.1 mL of a stock solution of 0.375 M methanol (0.0375 mmol) in CDCl3. The 
reaction mixture was stirred magnetically at rt. Its progress was checked periodically by withdrawing 
aliquots, diluting them with CDCl3 and analyzing by 1H NMR. Upon reaching approximately 50% 
conversion, the reaction mixture was directly loaded on column and purified by flash chromatography 
(CH2Cl2, then CH2Cl2/EtOAc). Enantiomeric enrichment of the deacylated product and the unreacted 
starting material was determined by chiral stationary phase HPLC (for HPLC conditions, see 
Characterization and HPLC Properties, 5.3.3). Each experiment in Section 5.4.2 was performed at least in 
duplicate.  
Table 5.4.2.1-1: KR of N-acyl thiolactams (±)-IV-2 using BTM: Optimization studya 
 
entry Catalyst R time,
d 
# 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1b none i-Pr 7 - ND ND ND ND <10k ND 
2c BTM i-Pr 4 
1 76.56 90.98 54.30 23.42 
55 26 
2 76.00 96.48 55.94 28.90 
3 
(R)-BTM + 
PhCO2H 
i-Pr 1 
1 93.28 84.67 47.58 77.58 
47 78 
2 93.24 85.16 47.74 77.94 
3 93.62 82.08 46.72 77.63 
4 93.78 82.74 46.87 80.75 
4d 
(R)-BTM + 
PhCO2H 
i-Pr 1 
1 93.08 89.56 48.77 84.98 
49 81 
2 92.80 87.44 48.51 77.02 
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5e 
(R)-BTM + 
PhCO2H 
i-Pr 1 
1 91.62 94.34 50.73 82.40 
50 84 
2 95.54 92.06 49.87 85.03 
6 
(R)-BTM + 
PhCO2H 
Et 1 
1 67.30 91.70 57.67 16.02 
57 15 
2 67.58 88.02 56.57 14.59 
7 
(R)-BTM + 
PhCO2H 
Ph 7 - ND ND ND ND <10k ND 
8f 
(R)-Cl-PIQ 
+ PhCO2H 
i-Pr 7 
1 63.86 36.26 36.22 6.42 
37 6.7 
2 65.28 40.98 38.57 7.06 
9g 
(S)-HBTM 
+ PhCO2H 
i-Pr 3 
1 61.56 53.40 46.45 7.06 
47 7.0 
2 60.86 54.12 47.07 6.95 
10h 
(R)-BTM + 
PhCO2H 
i-Pr 1 
1 86.50 82.56 48.83 35.43 
49 41 
2 89.12 83.90 48.49 45.94 
11i 
(R)-BTM + 
PhCO2H 
i-Pr 1 
1 93.04 85.82 47.98 76.75 
47 86 
2 94.84 81.22 46.13 95.09 
12j 
(R)-BTM + 
PhCO2H 
i-Pr 2 
1 30.28 22.10 42.19 2.29 
42 3.9 
2 57.64 40.24 41.11 5.46 
a)  See General Procedure, unless otherwise specified. b) To 0.05 mmol IV-2 in 0.4 mL CDCl3, 
0.1 mL stock solution of 0.375 M methanol in CDCl3 was added. c) To 0.05 mmol IV-2 in 0.2 
mL CDCl3, was added 0.2 mL of a stock solution of 0.025 M (R)-BTM (0.005 mmol) in CDCl3, 
followed by 0.1 mL of a stock solution of 0.375 M methanol (0.0375 mmol) in CDCl3.d)  0.0375 mmol 
PhCH2OH was used instead of methanol. e) 0.75 equiv (1-Naphthyl)2CHOH was used instead of 
methanol. f) 10 mol% of (R)-Cl-PIQ was used instead of (R)-BTM. g) 10 mol% (S)-HBTM was 
used instead of (R)-BTM. h) CD2Cl2was used instead of CDCl3. i)  Toluene was used instead of 
CDCl3. j) Diethyl ether was used instead of CDCl3. k) Estimated by 1H NMR. 
 
Table 5.4.2.1-2: Deacylation of N-isobutyryl-thiazolidine-2-thiones: Substrate scopea 
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entry R1 time # 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1 p-MeOC6H4 1 d 
1 93.96 88.40 48.48 94.91 
49 90 
2 93.08 89.50 49.02 84.83 
2 o-MeOC6H4 1 d 
1 95.56 83.98 46.78 117.31 
47 108 2 94.82 83.42 46.80 108.12 
3 94.74 83.76 46.92 98.08 
3 p-ClC6H4 16 hrs 
1 75.28 91.42 54.84 22.31 
54 23 
2 78.26 88.74 53.14 23.96 
4 o-ClC6H4 22 hrs 
1 85.90 85.50 49.88 35.95 
50 36 
2 86.10 85.68 49.88 36.66 
5 2-naphthyl 2 d 
1 73.82 99.08 57.30 34.08 
57 37 
2 75.92 99.30 56.67 39.52 
6 1-naphthyl 5 d 
1 86.32 76.62 47.02 31.41 
48 30 
2 84.62 79.78 48.53 29.17 
7 2-thienyl 1.5 d 
1 87.52 72.70 45.38 32.64 
45 32 
2 87.38 69.60 44.34 30.85 
8 
trans-
PhCH=CH 
1 d 
1 88.28 76.84 46.54 37.25 
47 37 
2 88.22 77.88 46.89 37.69 
9 CO2Me 15 hrs 
1 74.56 71.17 48.84 14.43 
49 15 
2 74.84 75.08 50.08 15.48 
10 i-Pr 7 d 
1 ND ND 0 ND 
0 ND 
2 ND ND 0 ND 
11 PhCH2 7 d 
1 14.92 6.02 28.75 1.43 
27 1.4 
2 15.92 5.26 24.83 1.45 
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7 
1 29.68 15.02 33.60 2.12 
33 2.3 
2 34.04 16.90 33.18 2.38 
a) See General Procedure. 
 
Table 5.4.2.1-3: Deacylation of N-isobutyryl-oxazolidine-2-thiones: Substrate scopea  
 
entry R1 time # 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1 Ph 2 d 1 94.18 53.20 36.10 56.85 36 57 
2 94.18 52.12 35.63 56.17 
2 p-MeOC6H4 4 d 
1 91.46 83.38 47.69 58.74 
47 59 
2 91.62 82.10 47.26 58.41 
3 o-MeOC6H4 6 d 
1 93.70 34.92 27.15 43.26 
30 38 
2 90.76 45.02 33.16 32.17 
4 p-ClC6H4 3 d 
1 67.54 86.08 56.03 13.92 
57 13 
2 61.62 86.84 58.49 11.44 
5 o-ClC6H4 3 d 
1 88.94 63.12 41.51 32.64 
43 32 
2 87.14 70.34 44.67 30.55 
6 CO2Me 4 d 
1 33.10 35.60 51.82 2.75 
53 2.6 
2 28.66 35.30 55.19 2.47 
7 CO2Me 1 d 
1 68.38 31.76 31.72 7.23 
29 7.9 
2 71.90 34.26 32.27 8.51 
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3 72.72 26.12 26.43 8.15 
4 71.84 22.80 24.09 7.61 
a) See General Procedure. 
 
5.4.2.2  Enantioselective N-acylation of thiolactam (±)-IV-15 
 
The previously published standard procedure was followed.4 Racemic thiazolidinethione IV-15 
(10.4 mg, 0.050 mmol) was dissolved almost completely in 0.4 mL of CDCl3 with gentle 
heating. The solution was allowed to cool to ambient temperature and stirred magnetically. A 0.1 
mL stock solution of 0.375M N,N-Diisopropylethylamine, 0.05 M (0.005 mmol, 10 mol%) of 
the specified catalyst was added, followed by isobutyric anhydride (6 μL, 5.6 mg, 0.0375 mmol). 
After stirring for several minutes, the solution became hazy. After the specified period of time, 
the reaction mixture was diluted with a small amount of methylene chloride, applied directly to a 
silica gel column, eluted, and analyzed as described above. The results are summarized in Table 
4S below. 
Table 5.4.2.2-1: Enantioselective N-acylation of thiolactam (±)-IV-15 
entry catalyst time # 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1 (R)-BTM  2 h 
1 53.16 19.46 26.80 3.94 
26 3.8 
2 50.68 17.00 25.12 3.60 
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2 (R)-Cl-PIQ  24 h 
1 19.96 1.62 7.51 1.52 
12 1.6 
2 21.20 4.20 16.54 1.60 
 
5.4.2.3  Enantioselective N-acylation of thiolactam (±)-IV-22. 
 
Racemic oxazolidinethione IV-22 (8.1 mg, 0.050 mmol) was dissolved in 0.3 mL of CDCl3. The 
solution was stirred magnetically and treated sequentially with a 0.1 mL of stock solution of 0.25 
M N,N-diisopropylethylamine (0.025  mmol) and 0.02 M (R)-BTM (0.002 mmol, 4 mol%), and 
0.1 mL stock solution of 0.25 M isobutyric anhydride (0.025 mmol). After the specified period 
of time, an aliquot of the reaction mixture was diluted with 1:1 hexane/methylene chloride and 
injected directly into HPLC (ODH, hexane/isopropanol 85:15, 1mL/min). The results are 
summarized in Table 5S below. 
Table 5.4.2.3-1: Enantioselective N-acylation of thiolactam (±)-IV-22 over time 
entry time # 
eePR  
% 
eeSM  
% 
CHPLC  
% 
s 
CAVG 
% 
sAVG 
1 0.5 h 
1 74.68 81.84 52.29 17.22 
50 16 
2 76.22 68.18 47.22 14.98 
2 1 h 
1 62.30 57.24 47.88 7.54 
48 7.2 
2 60.28 54.24 47.36 6.83 
3 3 h 
1 39.42 46.52 54.13 3.54 
54 4.1 
2 47.56 53.72 53.04 4.68 
4 8 h 1 33.12 35.74 51.90 2.75 50 2.7 
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2 33.16 31.30 48.56 2.65 
5 48 h - -2.98 3.80 56.05 1.10 - - 
 
5.4.2.4  N-Acyl exchange experiments 
 
Five vials were each charged with partially enantioenriched samples of (R)-IV-21 (0.037 mmol, 
82.06 % ee), (S)-IV-22 (0.037 mmol, 77.72 % ee) and 0.27 mL CDCl3.  Vial # 1 was charged 
with an additional 0.1 mL CDCl3 and left as a blank, Vial #2 was treated with 0.1 mL 0.037 M 
solution of (R)-BTM (0.92 mg, 0.0037mmol, 10 mol%) in CDCl3, Vial #3 with 0.1 mL 0.037M 
solution of (R)-BTM (0.92 mg, 0.0037 mmol, 10 mol%) and benzoic acid (0.46 mg, 0.0037 
mmol, 10 mol%) in CDCl3,Vial #4 with 0.1 mL 0.185 M solution of N,N-diisopropylethylamine 
(3.21 μL, 0.0185 mmol, 0.5 equiv) in CDCl3, and Vial #5 with 0.1 mL 0.037M solution of 
isobutyric acid (0.34 μL, 0.0037 mmol, 10 mol%) in CDCl3. All vials were left stirring at rt for 
24 h and analyzed by injecting directly into HPLC (OD-H, 85:15 hexane/isopropanol). The 
results are listed in Table 6S below. 
Table 5.4.2.4-1: Acyl exchange experiment 
entry additive 
(R)-IV-21 
%ee 
(S)-IV-22 
%ee 
1 none 81.32 76.90 
2 10 mol% (R)-BTM 2 17.94 13.58 
3 10 mol% (R)-BTM + BzOH 19.56 10.60 
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4 50 mol% i-Pr2NEt 81.16 74.44 
5 10 mol% i-PrCO2H 81.64 75.31 
 
5.4.3 Characterization and HPLC properties  
Note: Melting points and spectral data were determined using racemic samples. Signs of optical 
rotation are reported only in those cases when >0.01° absolute rotation was recorded. The 
HPLC data refer to samples obtained in kinetic resolutions using (R)-BTM. 
 
Previously reported.2  1H NMR (300 MHz, CDCl3): δ  7.60 (br s, 1H), 7.50–7.40 
(m, 5H), 5.35–5.25 (m, 1H), 3.85 (dd, J1 = 11.2 Hz, J2 = 8.0 Hz, 1H), 3.51 (dd, J1 
= 11.2 Hz, J2 = 8.3 Hz, 1H). 
 
 
 
Previously reported.2 1H NMR (300 MHz, CDCl3): δ 7.40–7.30 (m, 5H), 6.24 
(dd, J1=8.2 Hz, J2=1.6 Hz, 1H), 3.93 (dd, J1=11.3 Hz, J2=8.2 Hz. 1H), 3.38 (dq, 
J1=18.1 Hz, J2=7.3 Hz, 1H), 3.20 (dq, J1=18.1 Hz, J2=7.3 Hz, 1H), 3.07 (dd, 
J1=11.3 Hz, J2=1.6 Hz, 1H), 1.13 (t, J=7.3 Hz, 3H); HPLC (OD-H, 
hexane/isopropanol 95:5): 25.8 min (major); 27.8 min (minor). 
 
 
Previously reported.4 1H NMR (300 MHz, CDCl3): δ 7.41-7.26 (m, 5H), 6.15 
(dd, J1 = 8.1 Hz, J2 = 2.4 Hz, 1H), 4.52-4.43 (m, 1H), 3.88 (m, 1H), 3.09 (dd, J1 
= 8.4 Hz, J2 = 2.4 Hz, 1H), 1.21-1.12 (m, 6H). 
 
 
 
Yellow solid; mp: 159-161 °C; 1H NMR (300 MHz, CDCl3): δ 7.77 (d, 2H, J= 
8.2 Hz), 7.54-7.35 (m, 8H), 5.94 (app. t, J= 7.9, 2H), 3.84 (dd, J1=11.4 Hz, 
J2=7.3 Hz, 2H), 3.56 (dd, J1=11.4 Hz, J2=8.2 Hz, 1H); 13C NMR (75 MHz, 
CDCl3): δ 202.1, 171.3, 137.8, 133.8, 133.0, 129.7, 129.1, 128.8, 128.4, 126.3, 
71.7, 38.1; IR (KBr, cm-1): 3061, 3031, 1699, 1598, 1494, 1449, 1366, 1335, 
1316, 1288, 1268; MS: HR-ESI calculated for [(C16H13NOS2)+H]+: 300.0503, 
found: 300.0511. 
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White solid; mp: 115-118 ºC; 1H NMR (300 MHz, CDCl3): δ 7.87 (s, 
broad, 1H), 7.29 (d, J= 8.8 Hz, 2H), 6.92 (d, J= 8.5 Hz, 2H), 5.27 (app. t, 
J= 8.2 Hz, 1H), 3.79 (s, 3H), 3.78 (dd, J1= 11.1 Hz;  J2= 7.9 Hz, 1H), 3.47 
(dd, J1= 11.1 Hz, J2= 8.5 Hz, 1H);  13C NMR (75 MHz, CDCl3): δ 160.2, 
129.7, 127.6, 114.6, 67.1, 55.4, 41.6; IR (KBr, cm-1): 3136, 3001, 2956, 
2934, 2835, 1611, 1586, 1514, 1478, 1303, 1250; MS: HR-ESI calculated for 
[(C10H11NOS2)+H]+: 226.0355, found: 226.0357; HPLC (OD-H, hexane/isopropanol 4:1): 16.2 
min (minor); 25.1 min (major); (+) sign of rotation.  
 
 Yellow crystals; mp: 109-111 ºC;  1H NMR (300 MHz, CDCl3): δ 7.26 
(d, J= 8.8 Hz, 2H), 6.87 (d, J= 8.5 Hz, 2H), 6.08 (dd, J1= 7.9 Hz, J2=2 .6 
Hz, 1H), 4.42 (m, 1H), 3.83 (dd, J1= 11.1 Hz, J2= 7.9 Hz, 1H), 3.80 (s, 
3H), 3.06 (dd, J1= 11.4 Hz, J2= 2.9 Hz, 1H), 1.15 (d, J= 6.7 Hz, 3H), 1.09 
(d, J= 6.7 Hz, 3H);  13C NMR (75 MHz, CDCl3): δ 201.9, 179.0, 159.6, 
131.2, 129.9, 114.3, 70.1, 55.3, 36.7, 34.3, 19.3, 19.2; IR (KBr, cm-1): 
2967, 2929, 1699, 1611, 1513, 1464, 1314, 1303, 1250; MS: HR-ESI calculated for 
[(C14H17NO2S2)+H]+: 296.0773, found: 296.0768;  HPLC (OD-H, hexane/isopropanol 9:1): 10.5 
min (minor); 13.9 min (major); (−) sign of rotation. 
 
Off-white solid; mp: 142-145 °C; 1H NMR (300 MHz, CDCl3): δ 7.64 (s, broad, 
1H), 7.31 (m, 2H), 6.96 (m, 2H), 5.65 (app. t, J= 7.6 Hz, 1H), 3.93 (dd, J1= 11.1 
Hz;  J2= 8.1 Hz, 1 H), 3.84 (s, 3H), 3.46 (dd, J1= 11.1 Hz, J2= 7.6 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ 201.8, 156.1, 129.9, 126.0, 120.9, 110.7, 61.7, 55.5, 
39.8; IR (KBr, cm-1): 3133 (br), 2937, 1601, 1491, 1461, 1289, 1245; MS: HR-
ESI calculated for [(C10H11NOS2)+H]+: 226.0355, found: 226.0343; HPLC (AD-H, 
hexane/isopropanol 9:1): 9.6 min (minor); 12.9 (major); (+) sign of rotation.  
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.29 (m, 1H), 7.10 (d, J= 7.0 Hz, 
1H), 6.93 (m, 2H), 6.44 (app. d, J= 7.9 Hz, 1H), 4.51 (m, 1H), 3.81 (s, 3H), 3.80  
(dd, J1= 11.1 Hz, J2= 7.9 Hz, 1H), 3.05 (dd, J1= 11.1 Hz, J2= 1.5 Hz, 1H), 1.20 
(distereotpic doublets, 6H); 13C NMR (75 MHz, CDCl3): δ 203.3, 178.6, 155.6, 
129.4, 126.5, 125.1, 120.6, 110.8, 66.0, 55.5, 35.7, 33.9, 19.6, 19.1; IR (KBr, cm-
1): 3425 (br), 2969, 2918, 1702, 1492, 1462; MS: HR-ESI calculated for 
[(C14H17NO2S2)+H]+: 296.0773, found: 296.0771; HPLC (OD-H, hexane/isopropanol 9:1): 6.6 
min (major); 7.7 min (minor); (−) sign of rotation. 
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White solid; mp: 127-130 ºC; 1H NMR (300 MHz, CDCl3): δ 8.13 (s, broad, 
1H), 7.33 (m, 4H), 5.29 (app. t, J= 7.9 Hz, 1H), 3.85 (dd, J1= 11.1 Hz, J2= 
8.2 Hz, 1H), 3.43 (dd,  J1= 11.1 Hz, J2= 8.2 Hz, 1H);  13C NMR (75 MHz, 
CDCl3): δ 201.5, 136.5, 135.0, 129.5, 127.6, 66.7, 41.4; IR (KBr, cm-1): 
3134 (br), 2940, 1491, 1411, 1288, 1263; MS: HR-ESI calculated for 
[(C9H8ClNS2)+H]+: 229.9859, found: 229.9861; HPLC (OD-H, hexane/isopropanol 4:1): 12.9 
min (minor); 22.8 min (major); (+) sign of rotation.  
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.36-7.25 (m, 4H), 6.11 (dd, 
J1=7.9 Hz, J2=1.8 Hz, 1H), 4.45 (m, J= 6.7 Hz, 1H), 3.88 (dd, J1= 11.1 Hz, 
J2= 3.9 Hz, 1H), 3.04 (dd, J1= 11.4 Hz, J2= 2.3 Hz, 1H), 1.17 (d, J= 6.7 Hz, 
3H), 1.13 (d, J= 6.7 Hz Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 202.7, 
178.5, 136.1, 131.5, 130.3, 129.5, 127.3, 125.7, 67.8, 35.2, 33.9, 19.6, 18.9. 
IR (KBr, cm-1): 3281 (br), 2974, 2933, 2870, 1701, 1492, 1466, 1348, 1309, 
1257, 1230; MS: HR-ESI calculated for [(C13H14ClNOS2)+H]+: 300.0278, found: 300.0280; 
HPLC (OD-H, hexane/isopropanol 95:5): 15.47 min (minor); 17.01 min (major); (−) sign of 
rotation. 
 
White solid; mp:144-147 °C; 1H NMR (300 MHz, CDCl3): δ 8.40 (s, broad, 
1H), 7.69 (m, 1H), 7.45-7.23 (m, 3H), 5.68 (dd, J1= 8.5 Hz, J2= 5.9 Hz, 1H), 
4.04 (dd, J1= 11.4 Hz, J2= 8.5 Hz, 1H), 3.35 (dd, J1= 11.4 Hz, J2= 6.2 Hz, 1H);  
13C NMR (75 MHz, CDCl3): δ  202.4, 135.6, 131.9, 130.2, 130.1, 127.7, 126.9, 
63.6, 40.1; IR (KBr, cm-1): 3359, 3143, 3058, 2937, 1613, 1474, 1436, 1296, 
1262; MS: HR-ESI calculated for [(C9H8ClNS2)+H]+: 229.9859, found: 229.9850; HPLC (OD-
H, hexane/isopropanol 4:1): 9.4 min (minor); 18.9 min (major); (+) sign of rotation.  
 
Yellow solid; mp: 67-70 °C; 1H NMR (300 MHz, CDCl3): δ 7.35 (m, 1H), 7.22-
7.15 (m, 3H), 6.40 (dd, J1= 8.2 Hz, J2= 1.5 Hz, 1H), 4.44 (m, 1H), 3.85 (dd, J1= 
11.4 Hz, J2= 8.2 Hz, 1H),  3.00 (dd, J1= 11.4 Hz, J2= 1.5 Hz, 1H), 1.14 
(distereotopic doublets, 6H); 13C NMR (75 MHz, CDCl3): δ 201.6, 178.9, 137.7, 
134.3, 129.2, 126.9, 69.7, 36.3, 34.1, 19.4, 19.1; IR (KBr, cm-1): 3380, 3288, 
3064, 2974, 2933, 2871, 1704, 1593, 1574, 1467, 1443, 1382, 1352, 1307, 1229; 
MS: HR-ESI calculated for [(C13H14ClNOS2)+H]+: 300.0278, found: 300.0273; HPLC (AD-H, 
hexane/isopropanol 100:1, 0.8 mL/min): 7.3 min (major); 9.0 min (minor); (−) sign of rotation.  
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White solid; mp: 196-197 °C (dec); 1H NMR (300 MHz, CDCl3): δ 7.85 (m, 
3H), 7.50 (m, 4H), 7.28 (s, broad, 1H), 6.03 (app. t, J= 7.7 Hz, 1H), 4.07 (dd, 
J1= 11.1 Hz, J2= 8.4 Hz, 1H), 3.53 (dd, J1= 11.1 Hz, J2= 6.8 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ  202.3, 134.2, 133.2, 129.7, 129.5, 127.2, 126.3, 
125.5, 123.5, 121.8, 63.8, 40.8; IR (KBr, cm-1): 3134 (br), 2922, 2852, 2357, 
2339, 1470, 1301, 1260; MS: HR-ESI calculated for [(C13H11NS2)+H]+: 246.0406, found: 
246.0395; HPLC ( AD-H, hexane/isopropanol 95:5):  21.8 min (minor); 28.1 min (major), (+) 
sign of rotation.   
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.93-7.81 (m, 3H), 7.61-7.43 (m, 
3H), 7.26 (m, 1H), 6.53 (dd, J1= 8.8 Hz, J2= 3.5 Hz, 1H), 4.94 (app. t, J= 8.8 
Hz, 1H), 4.73 (m,1H), 4.39 (dd, J1= 8.8 Hz, J2= 3.5 Hz, 1H), 1.24 
(distereotopic doublets, 6H); 13C NMR (75 MHz, CDCl3): δ  185.7, 178.0, 
134.2, 133.8, 129.6, 129.4, 129.2, 127.0, 126.2, 125.5, 121.8, 58.9, 32.9, 19.4, 
18.9; IR (KBr, cm-1): 3453 (br), 2971, 2919, 2340, 2358, 1703, 1366, 1318; 
MS: HR-ESI calculated for [(C17H17NOS2)+H]+: 316.0817, found: 316.0824; HPLC ( OD-H, 
hexane/isopropanol 9:1, ):  19.5 min (minor); 27.2 min (major); (−) sign of rotation. 
 
White solid; mp: −(dec); 1H NMR (300 MHz, CDCl3): δ 7.88 (m, 4H), 
7.56-7.47 (m, 3H), 7.45 (s, broad, 1H), 5.48 (app. t, J= 8.2 Hz, 1H), 3.92 
(dd, J1= 11.1 Hz, J2= 7.9 Hz, 1H), 3.61 (dd, J1= 11.4 Hz, J2= 8.5 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ 201.9, 135.2, 133.5, 133.2, 129.6, 128.1, 
127.9, 127.0, 126.9, 125.6, 123.3, 67.5, 41.6, 29.7; IR (KBr, cm-1): 3440 
(br), 2919, 2850, 1659 (br); MS: HR-ESI calculated for [(C13H11NS2)+H]+: 246.0406, found: 
246.0393; HPLC (OD-H, hexane/isopropanol 4:1): 34.2 min (minor); 39.2 min (major); (+) sign 
of rotation.   
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.83 (m, 3H), 7.47 (m, 2H), 
6.31 (dd, J1= 8.2 Hz, J2= 2.3 Hz, 1H), 4.52 (m, 1H), 3.92 (dd, J1= 11.1 Hz, 
J2= 8.5 Hz, 1H), 3.17 (dd, J1= 11.1 Hz, J2= 2.0 Hz, 1H), 1.19 (d, J= 6.7 Hz, 
3H), 1.14 (d, J= 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 201.9, 178.9, 
136.5, 133.1, 129.1, 128.2, 127.7, 126.6, 126.5, 124.7, 123.3, 70.6, 36.4, 
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34.2, 19.3, 19.2; IR (KBr, cm-1): 3455 (br), 2967, 2341, 1698, 1334; MS: HR-ESI calculated for 
[(C17H17NOS2)+H]+: 316.0824, found: 316.0818; HPLC (AD-H, hexane/isopropanol 100:1):  
14.6 min (minor); 24.0 min (major); (−) sign of rotation.  
 
White solid; mp: 140-144 °C; 1H NMR (300 MHz, CDCl3):  δ 7.34 (d, J=5.0 Hz, 
1H), 7.12 (d, J= 2.9 Hz, 1H), 7.01 (m, 1H), 5.58 (app. t, J= 7.9 Hz, 1H), 3.87 
(dd, J1= 11.1 Hz, J2= 7.6 Hz, 1H), 3.62 (dd, J1= 11.1 Hz, J2= 8.2 Hz, 1H); 13C 
NMR (75 MHz, CDCl3): δ 200.9, 140.3, 127.3, 126.5, 126.2, 62.7, 41.8 ; IR 
(KBr, cm-1): 3444 (br), 2085 (br), 1636, 1484; MS: HR-ESI calculated for 
[(C7H7NS3)+H]+: 201.9811, found: 201.9813. HPLC: (OD-H, hexane/isopropanol 4:1):  13.4 
min (minor); 18.6 min (major); (+) sign of rotation.   
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.25 (d, J= 6.2 Hz, 1H), 7.16 (d, J= 
3.5 Hz, 1H), 6.96 (m, 1H), 6.51 (dd, J1= 7.5 Hz, J2= 1.3 Hz, 1H), 4.40 (m, 1H), 
3.88 (dd, J1= 11.4 Hz, J2= 7.5 Hz, 1H), 3.24 (dd, J1= 11.4 Hz, J2= 1.8 Hz, 1H), 
1.18 (d, J= 7.0 Hz, 3H), 1.12 (d, J= 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
200.4, 178.6, 140.7, 126.6, 126.4, 125.4, 65.9, 36.4, 33.9, 19.3, 19.1; IR (KBr, 
cm-1): 3455 (br), 2970, 2917, 2341, 1697, 1329, 1299; MS: HR-ESI calculated for 
[(C11H13NOS3)+H]+: 272.0232, found: 272.0230; HPLC (OD-H, hexane/isopropanol 9:1): 13.2 
min; (major); 14.3 min (minor); (−) sign of rotation. 
 
White solid; mp: 154-157 °C; 1H NMR (300 MHz, CDCl3��  δ 7.42- .27 
(m, 5H), 6.69 (d, J= 15.8 Hz, 1H), 6.25 (dd, J1= 15.5 Hz, J2=7.9 Hz, 1H), 
4.94 (app.q, J= 7.9 Hz, 1H), 3.72 (dd, J1= 11.1 Hz, J2= 7.9 Hz, 1H), 3.43 
(dd, J1= 11.1 Hz, J2= 7.9 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 201.4, 
134.5, 133.7, 130.2, 128.8, 128.7, 128.5, 126.8, 124.3, 66.0, 39.3; IR (KBr, 
cm-1): 3105, 2672, 2565, 1686, 1492, 1454, 1427, 1326, 12923072; MS: HR-ESI calculated for 
[(C11H11NS2)+H]+: 222.0402, found: 222.0406; HPLC (OD-H, hexane/isopropanol 4:1):  20.1 
min (major);  30.6 min (minor); (+)sign of rotation.   
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.41 -7.24 (m, 5H), 6.71 (d, 
J=15.8 Hz, 1H), 6.37 (dd, J1= 15.8 Hz, J2= 7.3 Hz, 1H), 5.81 (app t, J= 8.2 
Hz, 1H), 4.44 (m, 1H), 3.72 (dd, J1= 11.4 Hz, J2= 7.6 Hz, 1H), 3.03 (dd, J1= 
11.4 Hz, J2= 1.8 Hz, 1H), 1.20 (distereotopic doublets, 6H); 13C NMR (75 
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MHz, CDCl3): δ 200.9, 178.9, 135.6, 134.0, 128.7, 128.4, 126.8, 123.7, 68.9, 347.6, 34.0, 19.4, 
19.2; IR (KBr, cm-1): 3285 (br), 2973, 2932, 1698, 1494, 1466, 1448, 1392, 1327, 1313, 1250; 
MS: HR-ESI calculated for [(C15H17NOS2)+H]+: 292.0824, found: 292.0819; HPLC (OD-H, 
hexane/isopropanol 9:1): 10.8 min (minor); 17.5 min (major); (−) sign of rotation.  
 
Previously reported.5 1H NMR (90 MHz, CDCl3): δ 7.8-8.3 (br, 1H), 4.85 (app. t, J 
= 7.5 Hz, 1H), 3.90 (s, 3 H), 3.85 (d, 2 H, J = 7.5 Hz, 2H); HPLC (OD-H, 
hexane/isopropanol 4:1): 14.6 min (minor); 17.6 min (major).  
 
 
Yellow solid; mp: 97-100 °C; 1H NMR (300 MHz, CDCl3): δ 5.60 (m, 1H), 4.46 
(m, 1H), 3.78 (s, 3H), 3.65 (m, 1H), 3.34 (m, 1H), 1.18 (m, 6H); 13C NMR (75 
MHz, CDCl3): δ 200.0, 179.1, 168.9, 67.7, 53.3, 33.8, 30.8, 19.2, 18.9; IR (KBr, 
cm-1): 3439 (br), 2918, 1753, 1702, 1355, 1314; MS: HR-ESI calculated for 
[(C9H13NO3S2)+H]+: 248.0415, found: 248.0411; HPLC (AD-H, 
hexane/isopropanol 99:1):  14.9 min (minor);  18.4 min (major); (−) sign of rotation. 
 
Previously reported.1 1H NMR (300 MHz, CDCl3): δ 9.05 (br s, 1H), 4.11 (m, 
lH), 3.53(dd, J1 =11.0 Hz, J2 = 8.2 Hz, 1H), 3.32 (dd, J1 =11.0 Hz, J2 = 8.2 Hz, 
1H), 2.01 (m, lH), 1.03 (d, J = 8.5 Hz, 3H), 1.00 (d, J = 7.2 Hz, 3H). 
 
 
Yellow oil; 1H NMR (300 MHz, CDCl3): δ 5.14 (m (app. t), 1H), 4.49 (m, 1H), 
3.48 (dd, J1= 11.4 Hz, J2= 7.9 Hz, 1H), 2.66 (dd, J1= 11.4 Hz, J2= 1.5 Hz, 1H), 
2.33 (m, 1H), 1.23 (d, J= 6.7 Hz, 3H), 1.16 (d, J= 6.7 Hz, 3H), 1.05 (d, J= 6.7 
Hz, 3H), 0.96 (d, J= 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 202.5, 178.8, 
71.9, 33.3, 30.7, 30.3, 19.9, 19.2, 19.0, 17.7; IR (KBr, cm-1): 3288, 3159, 2966, 
2933, 2873, 1810, 1740, 1698, 1467, 1353, 1277, 1254; MS: HR-ESI calculated for 
[(C10H17NOS2)+H]+: 232.0824, found: 232.0827. 
 
Previously reported.2 1H NMR (300 MHz, CDCl3): δ 7.45 (br s, 1H), 7.40–
7.26 (m, 3H), 7.23–7.17 (m, 2H), 4.52–4.40 (m, 1H), 3.60 (dd, J1= 11.2 Hz, 
J2= 7.7 Hz, 1H), 3.33 (dd, J1= 11.2 Hz, J2= 6.8 Hz, 1H), 3.03 (dd, J1= 13.6 Hz, 
J2= 7.6 Hz, 1H), 2.98 (dd, J1= 13.6 Hz, J2= 6.7 Hz, 1H); HPLC (OD-H, 
hexane/isopropanol 4:1):  11.5 min (major); 14.0 min (minor).  
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Yellow oil; 1H NMR (300 MHz, CDCl3): δ 7.31 (m, 5H), 5.31 (m, 1H), 4.47 
(m, 1H), 3.36 (dd, J1= 7.3 Hz, J2= 6.4 Hz, 1H), 3.22 (dd, J1= 13.2 Hz, J2= 3.8 
Hz, 1H), 3.03 (dd, J1= 12.9 Hz, J2= 10.3 Hz, 1H), 2.87 (app. d, J= 12.3 Hz, 
1H), 1.21 (distereotopic doublets, 6H); 13C NMR (75 MHz, CDCl3): δ 201.1, 
179.0, 136.6, 129.5, 128.9, 127.2, 69.2, 36.8, 33.6, 31.9, 19.7, 19.1; IR (KBr, cm-1): 3278 (br), 
3146 (br), 3026, 2973, 2932, 2871, 1698, 1495, 1467, 1342, 1259; MS: HR-ESI calculated for 
[(C14H17NOS2)+H]+: 280.0824, found: 280.0827; HPLC (OD-H, hexane/isopropanol 95:5):  9.9 
min (minor); 11.4 min (major).  
 
Previously reported.6 1H NMR (300 MHz, CDCl3): δ 8.69-8.49 (bs, 1H), 7.34 
(m, 4H), 5.61 (d, J = 8.3 Hz, 1H), 4.80 (ddd, J1 = 8.3 Hz, J2 = 7.6 Hz, J3=3.3 
Hz, 1H), 3.50 (dd, J1 = 17.1 Hz, J2=7.6 Hz, 1H), 3.28 (dd, J1 = 17.1 Hz, J2 = 
3.3 Hz, 1H); HPLC (OD-H, hexane/isopropanol 4:1):  12.9 min (minor); 23.1 
min (major).  
 
Yellow solid; mp: 100-102 °C; 1H NMR (300 MHz, CDCl3): δ 7.31 (m, 4H), 
6.54 (d, J= 7.0 Hz, 2H), 4.54 (m, 2H), 3.38 (dd, J1= 17.0 Hz, J2= 6.4 Hz, 1H), 
3.15 (app. d, J= 17.0 Hz, 1H), 1.26 (distereotopic doublets, 6H); 13C NMR 
(75 MHz, CDCl3): δ 200.9, 179.9, 139.2, 138.9, 129.4, 128.1, 125.9, 125.1, 
76.2, 46.8, 36.4, 33.6, 19.5, 19.4; IR (KBr, cm-1): 2972, 2932, 2870, 1695, 
1460, 1382, 1346, 1250; MS: HR-ESI calculated for [(C14H15NOS2)+H]+: 278.0668, found: 
278.0663; HPLC (AD-H, hexane/isopropanol 95:5): 6.5 min (major); 8.4 min (minor).  
 
Previously reported.1 1H NMR (300 MHz, CDCl3): δ 8.30 (br s, 1H), 7.28-7.41 
(m, 5H), 5.14 (dd, J1 = 9.2 Hz, J2 = 6.9 Hz, 1H), 4.98 (t, J = 9.0 Hz, 1H), 4.45 
(dd, J1 = 8.8 Hz, J2 = 6.9 Hz, 1H); HPLC (OD-H, hexane/isopropanol 10:1):  
30.0 min (minor); 52.0 min (major); (+) sign of rotation.  
 
 
Previously reported.4 1H NMR (300 MHz, CDCl3): δ 7.41-7.25 (m, 5H), 5.69 
(dd, J1 = 9.0 Hz, J2 =3.9 Hz, 1H), 4.78 (t, J = 9.0 Hz, 1H), 4.66-4.57 (m, 1H), 
4.41 (dd, J1 = 9.0 Hz, J2 = 3.9 Hz, 1H), 1.17 (d, J = 6.9Hz, 3H), 1.12 (d, J = 
6.9Hz, 3H); HPLC (OD-H, hexane/isopropanol 20:1):  16.1 min (major); 22.0 
min (minor). 
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Yellow solid; mp: 94-97 °C; 1H NMR (300 MHz, CDCl3): δ 8.53 (s, 
broad, 1H), 7.15 (d, J= 8.5 Hz, 2H), 6.83 (d, J= 8.8 Hz, 2H), 5.03 (dd, J1= 
9.0 Hz, J2= 7.3 Hz, 1H), 4.86 (app. t, J= 9.1 Hz, 1H), 4.32  (dd, J1= 8.8 Hz, 
J2= 6.7 Hz, 1H), 3.72 (s, 3H); 13CNMR (75MHz, CDCl3): δ 189.4, 159.9, 
129.9, 127.6, 114.6, 76.9, 59.7, 55.4; IR (KBr, cm-1): 3272 (br), 2932, 
2958, 1657, 1611, 1513, 1250; MS: HR-ESI calculated for [(C10H11NO2S)+H]+: 210.0579, 
found: 210.0583; HPLC (OD-H, hexane/isopropanol 4:1): 15.2 min (minor); 24.0 min (major); 
(+) sign of rotation.  
 
White solid; mp: 100-103 °C; 1H NMR (300 MHz, CDCl3): δ 7.20 (d, 
J=8.5 Hz, 2H), 6.87 (d, J=8.5 Hz, 2 H), 5.62 (dd, J1= 8.5 Hz, J2= 3.8 Hz, 
1H), 4.73 (app. t, J= 8.8 Hz, 1H), 4.57 (m, 1H), 4.38 (dd, J1= 9.1 Hz, 
J2=4.1 Hz, 1H), 3.76 (s, 3H), 1.14 (d, J= 6.7 Hz, 3H), 1.07 (d, J= 6.7 Hz, 
3H); 13C NMR (75 MHz, CDCl3): δ 185.2, 178.1, 159.8, 130.5, 127.5, 
114.5, 73.8, 61.9, 55.3, 32.9, 19.1, 18.5; IR (KBr, cm-1): 2973, 2934, 2873, 
2836, 1706, 1612, 1586, 1515, 1466, 1365; MS: HR-ESI calculated for [(C14H17NO3S)+H]+: 
280.0999, found: 280.1002; HPLC (OD-H, hexane/isopropanol 95:5): 23.9 min (minor); 27.1 
min (major); (−) sign of rotation. 
 
Colorless oil; 1H NMR (300 MHz, CDCl3): δ 8.44 (s, broad, 1H), 7.30 (m, 2H), 
6.97 (m, 1H), 6.88 (d, J= 8.2 Hz, 1H), 5.38 (dd, J1=9.4 Hz, J2=6.7 Hz, 1H), 4.99 
(dd, J1= 9.4 Hz, J2= 9.1 Hz, 1H), 4.43 (dd, J1= 9.1 Hz, J2= 6.7 Hz, 1H), 3.82 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ 190.1, 156.3, 129.9, 126.1, 125.8, 120.9, 
110.6, 76.6, 55.5, 55.4; IR (KBr, cm-1): 3180 (br), 2965, 1590, 1493, 1462, 1246 
; MS: HR-ESI calculated for [(C10H11NO2S)+H]+: 210.0580, found: 210.0583; HPLC (AD-H, 
hexane/isopropanol 95:5):  19.0 min (minor);  31.1 min (major); (+) sign of rotation.  
 
White solid; mp: 97-99 °C; 1H NMR (300 MHz, CDCl3): δ 7.29 (m, 1H), 7.05 
(m, 1H), 6.93 (m, 2H), 5.93 (dd, J1= 9.1 Hz, J2= 3.8 Hz, 1H), 4.70 (m, 2H), 4.33 
(dd, J1= 9.1 Hz, J2= 4.4 Hz, 1H), 3.85 (s, 3H), 1.18 (distereotopic doublets, 6H); 
13C NMR (75 MHz, CDCl3): δ 186.0, 178.0, 156.3, 129.8, 126.5, 126.0, 120.8, 
110.9, 73.0, 58.6, 55.5, 32.7, 19.3, 18.6; IR (KBr, cm-1): 3404 (br), 2970, 2920, 
2849, 2341, 2360, 1704, 1603, 1493, 1464, 1336, 1297; MS: HR-ESI calculated 
for [(C14H17NO3S)+H]+: 280.0998, found: 280.1002; HPLC (OD-H, hexane/isopropanol 95:5):  
13.9 min (major); 16.1 min (minor); (−) sign of rotation.  
117 
 
White powder; mp: 147-149 °C; 1H NMR (300 MHz, CDCl3): δ 8.12 (s, 
broad, 1H), 7.39 (d, J= 8.5 Hz, 2H), 7.26 (d, J= 8.2 Hz, 2H), 5.12 (dd, J1= 
9.1 Hz, J2= 6.7 Hz, 1H), 4.99 (app.t, J= 9.1 Hz, 1H), 4.43 (dd, J1= 8.5 Hz, 
J2= 6.7 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 189.9, 136.4, 135.2, 129.6, 
127.6, 59.6; IR (KBr, cm-1): 3190 (br), 1654, 1492, 1417, 1262; MS: HR-
ESI calculated for [(C9H8ClNOS)+H]+: 214.0085, found: 214.0088; HPLC (OD-H, 
hexane/isopropanol 4:1):  12.8 min (minor); 24.7 min (major); (+) sign of rotation.  
 
Colorless oil; 1H NMR (300 MHz, CDCl3): δ 7.35 (d, J=8.5 Hz, 2H), 7.23 
(d, J= 8.5 Hz, 2H), 5.66 (dd, J1= 8.8 Hz, J2= 3.8 Hz, 1H), 4.78 (app. t, J= 8.8 
Hz, 1H), 4.59 (m, 1H), 4.38 (dd, J1= 8.5 Hz, J2= 3.8 Hz, 1H), 1.18 (d, J= 6.7 
Hz, 3H), 1.12 (d, J= 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 184.9, 
178.1, 137.1, 134.8, 129.4, 127.4, 73.3, 61.7, 32.8, 19.1, 18.6; IR (KBr, cm-
1): 3411 (br), 2973, 2920, 1706, 1494, 1467, 1347, 1332, 1293; MS: HR-ESI 
calculated for [(C13H14ClNO2S)+H]+: 284.0503, found: 284.0507; HPLC (OD-H, 
hexane/isopropanol 9:1):  18.7 min (major);  23.7 min (minor); (−) sign of rotation. 
 
White solid; mp: 95-97 °C; 1H NMR (300 MHz, CDCl3): δ 8.63 (s, broad, 1H), 
7.45-7.26 (m, 4H), 5.53 (m, 1H), 5.10 (app. t, J= 9.1 Hz, 1H), 4.42 (m, 1H);  13C 
NMR (75 MHz, CDCl3): δ 190.3, 135.8, 131.9, 130.1, 130.0, 127.8, 126.4, 76.6, 
57.2; IR (KBr, cm-1): 3242 (br), 2923, 1654, 1596, 1507, 1475, 1438, 1260; MS: 
HR-ESI calculated for [(C9H8ClNOS)+H]+: 214.0084, found: 214.0088; HPLC 
(AD-H, hexane/isopropanol 97:3):  25.4 min (minor);  28.9 min (major); (+) sign of rotation.  
 
White solid; mp:124-126 °C; 1H NMR (300 MHz, CDCl3): δ 7.42 (m, 1H), 7.28 
(m, 2H), 7.09 (m, 1H), 6.09 (dd, J1= 8.8 Hz, J2= 3.5 Hz, 1H), 4.82 (app. t, J= 8.5 
Hz, 1H), 4.67 (m, 1H), 4.35 (dd, J1= 10.0 Hz, J2= 4.1 Hz, 1H), 1.23 
(distereotopic doublets, 6H); 13C NMR (75 MHz, CDCl3): δ 185.5, 177.9, 135.8, 
131.9, 130.3, 129.8, 127.6, 125.4, 72.9, 59.6, 32.7, 19.2, 18.8; IR (KBr, cm-1): 
3530 (br), 2871, 2922, 2851, 1467, 1445, 1365, 1327, 1298; MS: HR-ESI 
calculated for [(C13H14ClNO2S)+H]+: 284.0506, found: 284.0507; HPLC (AD-H, 
hexane/isopropanol 100:1):  10.2 min (major); 15.2 min (minor); (−) sign of rotation. 
 
Previously reported.5 1H NMR (90 MHz, CDCl3): δ 8.98 (br, 1 H), 5.01 (m, 
118 
 
3 H); 3.96 (s, 3 H); HPLC (OD-H, hexane/isopropanol 7:3): 10.4 min (minor); 15.2 min (major).  
 
 
Clear and colorless oil; 1H NMR (300 MHz, CDCl3): δ 5.16 (dd, J1=9.4 Hz, 
J2=4.4 Hz, 1H), 4.62 (m, 2H), 4.48 (dd, J1= 9.4 Hz, J2= 4.4 Hz, 1H), 3.79 (s, 3H), 
1.25 (d, J= 6.7 Hz, 3H), 1.20 (d, J= 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
184.1, 178.5, 168.4, 68.4, 59.8, 53.3, 32.5, 18.9, 18.7; IR (KBr, cm-1): 3490 (br), 
2917, 1752, 1704, 1467, 1437, 1345, 1294; MS: HR-ESI calculated for 
[(C9H13NO4S)+H]+: 232.0638, found: 232.0636; HPLC (OD-H, hexane/isopropanol 4:1):  13.4 
min (major); 19.6 min (minor); (−) sign of rotation.  
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